

DescriptionBackground of the Invention

5 [0001] The present invention relates to phenyl acrylamide derivatives, to processes and intermediates for their preparation, to pharmaceutical compositions containing them and to their medicinal use. The compounds of the present invention are selective agonists and antagonists of serotonin 1 (5-HT₁) receptors. They are useful in treating or preventing migraine, depression and other disorders for which a 5-HT₁ agonist or antagonist is indicated.

10 [0002] European Patent Publication 434,561, published on June 26, 1991, refers to 7-alkyl, alkoxy, and hydroxy substituted-1-(4-substituted-1-piperazinyl)-naphthalenes. The compounds are referred to as 5-HT₁ agonists and antagonists useful for the treatment of migraine, depression, anxiety, schizophrenia, stress and pain.

15 [0003] European Patent Publication 343,050, published on November 23, 1989, refers to 7-unsubstituted, halogenated, and methoxy substituted-1-(4-substituted-1-piperazinyl)-naphthalenes as useful 5-HT_{1A} ligand therapeutics.

20 [0004] Glennon *et al.*, refers to 7-methoxy-1-(1-piperazinyl)-naphthalene as a useful 5-HT₁ ligand in their article "5-HT_{1D} Serotonin Receptors", *Clinical Drug Res. Dev.*, 22, 25-36 (1991).


25 [0005] Glennon's article "Serotonin Receptors: Clinical Implications", *Neuroscience and Behavioral Reviews*, 14, 3547 (1990), refers to the pharmacological effects associated with serotonin receptors including appetite suppression, thermoregulation, cardiovascular/hypotensive effects, sleep, psychosis, anxiety, depression, nausea, emesis, Alzheimer's disease, Parkinson's disease and Huntington's disease.

30 [0006] World Patent Application WO 95/31988, published November 30, 1995, refers to the use of a 5-HT_{1D} antagonist in combination with a 5-HT_{1A} antagonist to treat CNS disorders such depression, generalized anxiety, panic disorder, agoraphobia, social phobias, obsessive-compulsive disorder, post-traumatic stress disorder, memory disorders, anorexia nervosa and bulimia nervosa, Parkinson's disease, tardive dyskinesias, endocrine disorders such as hyperprolactinaemia, vasospasm (particularly in the cerebral vasculature) and hypertension, disorders of the gastrointestinal tract where changes in motility and secretion are involved, as well as sexual dysfunction.

35 [0007] G. Maura *et al.*, *J. Neurochem.*, 66 (1), 203-209 (1996), have stated that administration of agonists selective for 5-HT_{1A} receptors or for both 5-HT_{1A} and 5-HT_{1D} receptors might represent a great improvement in the treatment of human cerebellar ataxias, a multifaceted syndrome for which no established therapy is available.

Summary of the Invention

40 [0008] The present invention relates to compounds of the formula




45 wherein R¹ is a group of the formula G¹, G², G³, G⁴ or G⁵, depicted below,


50

55

5



10




15

 G^1 G^2 G^3


20

25



30

or



35

 G^4 G^5

wherein E

is oxygen, sulfur, SO or SO_2 ;

40 R^6 is selected from the group consisting of hydrogen, (C_1-C_6) alkyl, $[(C_2-C_4)$ alkyl]aryl wherein the aryl moiety is phenyl, naphthyl, or heteroaryl- $(CH_2)_q$, wherein the heteroaryl moiety is selected from the group consisting of pyridyl, pyrimidyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl and benzisothiazolyl and q is zero, one, two, three or four, and wherein said aryl and heteroaryl moieties may optionally be substituted with one or more substituents independently selected from the group consisting of chloro, fluoro, bromo, iodo, (C_1-C_6) alkyl, (C_1-C_6) alkoxy, trifluoromethyl, cyano and $-SO_g(C_1-C_6)$ alkyl, wherein g is zero, one or two;

45 R^7 is selected from the group consisting of hydrogen, (C_1-C_6) alkyl, $[(C_2-C_4)$ alkyl]aryl wherein the aryl moiety is phenyl, naphthyl, or heteroaryl- $(CH_2)_q$, wherein the heteroaryl moiety is selected from the group consisting of pyridyl, pyrimidyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl and benzisothiazolyl and q is zero, one, two, three or four, and wherein said aryl and heteroaryl moieties may optionally be substituted with one or more substituents independently selected from the group consisting of chloro, fluoro, bromo, iodo, (C_1-C_6) alkyl, (C_1-C_6) alkoxy, trifluoromethyl, $-C(=O)-(C_1-C_6)$ alkyl, cyano and $-SO_j(C_1-C_6)$ alkyl, wherein j is zero, one or two;

50 or R^6 and R^7 taken together form a 2 to 4 carbon chain;

55 R^8 is hydrogen or (C_1-C_3) alkyl;

R^9 is hydrogen or (C_1-C_6) alkyl;

or R^6 and R^9 , together with the nitrogen atom to which they are attached, form a 5 to 7 membered ring; and p is one, two, or three;

R^2 is hydrogen, (C_1-C_4) alkyl, phenyl or naphthyl, wherein said phenyl or naphthyl may optionally be substituted with one or more substituents, preferably from zero to three substituents, independently selected from the group

consisting of chloro, fluoro, bromo, iodo, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, trifluoromethyl, cyano and -SO_g(C₁-C₆)alkyl, wherein g is zero, one or two;

5 R³ is -(CH₂)_mB, wherein m is zero, one, two or three and B is hydrogen, phenyl, naphthyl or a 5 or 6 membered heteroaryl group containing from one to four hetero atoms in the ring (e.g., furyl, thienyl, thiazolyl, pyrazolyl, iso-

thiazolyl, oxazolyl, isoxazolyl, pyrrolyl, triazolyl, tetrazolyl, imidazolyl, 1,3,5-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-oxadiazolyl, 1,3,5-thiadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl,

10 1,2,4-triazinyl, 1,2,3-triazinyl, 1,3,5-triazinyl, benzoxazolyl, benzothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, thianaphthetyl, isothianaphthetyl, benzofuranyl, isobenzofuranyl, isoindolyl, indolyl, indazolyl, isoquinolyl, quinolyl, phthalazinyl, quinoxalinyl, quinazolinyl, benzoxazinyl; etc.), and wherein each of the foregoing aryl

15 and heteroaryl groups may optionally be substituted with one or more substituents, preferably from zero to three substituents, independently selected from the group consisting of chloro, fluoro, bromo, iodo, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, trifluoromethyl, cyano, hydroxy, -COOH and -SO_g(C₁-C₆)alkyl, wherein g is zero, one or two;

15 R⁴ is (C₁-C₆)alkyl or aryl or R³ and R⁴ may optionally be taken together with the nitrogen to which they are attached to form a five to seven membered heteroalkyl ring, wherein any two of the carbon atoms of said heteroalkyl ring

may optionally be replaced with a heteroatom selected from the group consisting of nitrogen, oxygen or sulfur (e.g., pyrrolidine, isoxazolidine, 1,3-oxazolidin-3-yl, isothiazolidine, 1,3-thiazolidin-3-yl, 1,2-pyrazolidin-2-yl, 1,3-pyrazolidin-1-yl, piperidine, thiomorpholine, 1,2-tetrahydrothiazin-2-yl, 1,3-tetrahydrothiazin-3-yl, tetrahydrothiadiazine, morpholine, 1,2-tetrahydroadiazin-2-yl, 1,3-tetrahydroadiazin-1-yl, piperazine, etc.); wherein said heteroalkyl

20 ring may optionally be substituted by aryl or heteroaryl (e.g., furyl, thienyl, thiazolyl, pyrazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrrolyl, triazolyl, tetrazolyl, imidazolyl, 1,3,5-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-oxadiazolyl, 1,3,5-thi-

25 adiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, 1,2,4-triazinyl, 1,2,3-triazinyl, 1,3,5-triazinyl, benzoxazolyl, benzothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, thianaphthetyl, isothianaphthetyl, benzofuranyl, isobenzofuranyl, isoindolyl, indolyl, indazolyl, isoquinolyl, quinolyl, phthalazinyl, quinoxalinyl, quinazolinyl, benzoxazinyl; etc.);

25 R⁵ is hydrogen, (C₁-C₆)alkyl or aryl, wherein aryl is selected from the group consisting of phenyl, naphthyl, pyridyl or pyrimidyl, wherein any of said aryl may optionally be independently substituted on any available bonding site by any of the radicals of X;

30 X is hydrogen, chloro, fluoro, bromo, iodo, cyano, (C₁-C₆)alkyl, hydroxy, trifluoromethyl, (C₁-C₆)alkoxy, -SO_m(C₁-C₆)alkyl wherein m is zero one or two, -CO₂R¹⁰ or -CONR¹¹R¹²;

35 each of R¹⁰, R¹¹ and R¹² is selected, independently, from the radicals set forth in the definition of R²; or R¹¹ and R¹², together with the nitrogen to which they are attached, form a 5 to 7 membered heteroalkyl ring that may contain from one to four heteroatoms selected from nitrogen, sulfur and oxygen (e.g., pyrrolidine, isoxazolidine, 1,3-oxazolidin-3-yl, isothiazolidine, 1,3-thiazolidin-3-yl, 1,2-pyrazolidin-2-yl, 1,3-pyrazolidin-1-yl, piperidine, thiomorpholine, 1,2-tetrahydrothiazin-2-yl, 1,3-tetrahydrothiazin-3-yl, tetrahydrothiadiazine, morpholine, 1,2-tetrahydroadiazin-2-yl, 1,3-tetrahydroadiazin-1-yl, piperazine, etc.);

40 the broken lines represent optional double bonds;
and the pharmaceutically acceptable salts thereof.

[0009] The present invention also relates to the pharmaceutically acceptable acid addition salts of compounds of the formula I. The acids which are used to prepare the pharmaceutically acceptable acid addition salts of the aforementioned base compounds of this invention are those which form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate, succinate, maleate, fumarate, glutonate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate [i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)] salts.

[0010] The invention also relates to base addition salts of formula I. The chemical bases that may be used as reagents to prepare pharmaceutically acceptable base salts of those compounds of formula I that are acidic in nature are those that form non-toxic base salts with such compounds. Such non-toxic base salts include, but are not limited to those derived from such pharmacologically acceptable cations such as alkali metal cations (e.g., potassium and sodium) and alkaline earth metal cations (e.g., calcium and magnesium), ammonium or water-soluble amine addition salts such as N-methylglucamine (meglumine), and the lower alkanolammonium and other base salts of pharmaceutically acceptable organic amines.

[0011] The compounds of this invention include all stereoisomers and all optical isomers of compounds of the formula I (e.g., R and S enantiomers), as well as racemic, diastereomeric and other mixtures of such isomers.


[0012] The compounds of this invention may contain olefin-like double bonds. When such bonds are present, the compounds of the invention exist as cis and trans configurations and as mixtures thereof.

[0013] Unless otherwise indicated, the alkyl and alkenyl groups referred to herein, as well as the alkyl moieties of other groups referred to herein (e.g., alkoxy), may be linear or branched, and they may also be cyclic (e.g., cyclopropyl,

cyclobutyl, cyclopentyl, or cyclohexyl) or be linear or branched and contain cyclic moieties. Unless otherwise indicated, halogen includes fluorine, chlorine, bromine, and iodine.

[0014] Preferred compounds of the formula I include those wherein R¹ is

5



10

and R⁶ is methyl.

[0015] Preferred compounds of the formula I also include those wherein R³ is substituted phenyl or -(CH₂)-substituted phenyl.

[0016] Preferred compounds of the formula I also include those wherein R² is hydrogen.

[0017] Preferred compounds of the formula I also include those wherein R⁵ is hydrogen or methyl.

[0018] Preferred compounds of the formula I also include those wherein R⁴ is hydrogen or methyl.

[0019] Preferred compounds of the formula I also include those wherein X is hydrogen, fluoro or chloro, preferably wherein X is hydrogen.

[0020] Examples of specific preferred compounds of the formula I are the following:

25 3-[2-(4-methylpiperazin-1-yl)phenyl]-2,N-diphenylacrylamide;
 3-[2-(4-methylpiperazin-1-yl)phenyl]-N-(4-trifluoro-methylphenyl)-acrylamide;
 N-(3,4-dichlorophenyl)-3-[2-(4-methylpiperazin-1-yl)phenyl]-acrylamide;
 N-(4-chlorobenzyl)-3-[2-(4-methylpiperazin-1-yl)phenyl]-2-phenylacrylamide; and
 N-(4-chlorobenzyl)-3-[2-(4-methylpiperazin-1-yl)phenyl]acrylamide.

30 [0021] Other compounds of formula I include the following:

N-(4-chlorobenzyl)-2-methyl-3-[2-(4-methylpiperazin-1-yl)phenyl]-acrylamide;
 N-benzyl-3-[2-[methyl-(2-pyrrolidin-1-ylethyl)amino]phenyl]-acrylamide;
 N-benzyl-3-[2-(2-pyrrolidin-1-yl-ethoxy)phenyl]-acrylamide;
 35 N-(4-chlorobenzyl)-3-[2-fluoro-6-(4-methylpiperazin-1-yl)phenyl]-acrylamide;
 N-(4-chlorobenzyl)-3-[4-fluoro-2-(4-methylpiperazin-1-yl)phenyl]-acrylamide;
 N-(4-chlorobenzyl)-3-[4-chloro-2-(4-methylpiperazin-1-yl)phenyl]-acrylamide;
 N-(4-chlorobenzyl)-3-[4-chloro-2-methyl-6-(4-methylpiperazin-1-yl)phenyl]-acrylamide;
 N-(4-chlorobenzyl)-3-[2-methyl-6-(4-methylpiperazin-1-yl)phenyl]-acrylamide;
 40 N-(4-chlorobenzyl)-3-[2-(1-methylpiperidin-4-yl)phenyl]-acrylamide;
 N-(4-chlorobenzyl)-3-[2-(1,4-dimethylpiperidin-4-yl)phenyl]-acrylamide;
 2-methyl-3-[2-(4-methylpiperazin-1-yl)phenyl]-but-2-enoic acid 4-chloro-benzylamide;
 3-[2-(4-methylpiperazin-1-yl)phenyl]-but-2-enoic acid 4-chlorobenzylamide;
 N-(4-chlorobenzyl)-3-[2-(4-methylpiperazin-1-yl)phenyl]-2-trifluoro-methylacrylamide;
 45 N-[1-(4-chlorophenyl)ethyl]-3-[2-(4-methylpiperazin-1-yl)-phenyl]-acrylamide;
 N-(4-chlorophenyl)-3-[2-(4-methylpiperazin-1-yl)phenyl]-acrylamide;
 N-benzyl-N-methyl-3-[2-(4-methylpiperazin-1-yl)phenyl]-acrylamide;
 N-benzyl-3-[2-[(2-dimethylaminoethyl)-methylamino]phenyl]-acrylamide;
 N-(4-chlorobenzyl)-2-methyl-3-[2-(4-methylpiperazin-1-yl)phenyl]-propylamide;
 50 N-benzyl-3-[2-[methyl-(2-pyrrolidin-1-ylethyl)amino]phenyl]-propylamide;
 N-benzyl-3-[2-(2-pyrrolidin-1-yl-ethoxy)phenyl]-propylamide;
 N-(4-chlorobenzyl)-3-[2-fluoro-6-(4-methylpiperazin-1-yl)phenyl]-propylamide;
 N-(4-chlorobenzyl)-3-[4-fluoro-2-(4-methylpiperazin-1-yl)phenyl]-propylamide;
 N-(4-chlorobenzyl)-3-[4-chloro-2-(4-methylpiperazin-1-yl)phenyl]-propylamide;
 55 N-(4-chlorobenzyl)-3-[4-chloro-2-methyl-6-(4-methylpiperazin-1-yl)phenyl]-propylamide;
 N-(4-chlorobenzyl)-3-[2-methyl-6-(4-methylpiperazin-1-yl)phenyl]-propylamide;
 N-(4-chlorobenzyl)-3-[2-(1-methylpiperidin-4-yl)phenyl]-propylamide;
 N-(4-chlorobenzyl)-3-[2-(1,4-dimethylpiperidin-4-yl)phenyl]-propylamide;

2-methyl-3-[2-(4-methylpiperazin-1-yl)phenyl]-but-2-anoic acid 4-chloro-benzylamide;
 3-[2-(4-methylpiperazin-1-yl)phenyl]-but-2-anoic acid 4-chlorobenzylamide;
 N-(4-chlorobenzyl)-3-[2-(4-methylpiperazin-1-yl)phenyl]-2-trifluoro-methylpropylamide;
 N-[1-(4-chlorophenyl)ethyl]-3-[2-(4-methylpiperazin-1-yl)-phenyl]-propylamide;
 5 N-(4-chlorophenyl)-3-[2-(4-methylpiperazin-1-yl)phenyl]-propylamide;
 N-(3,4-dichlorophenyl)-3-[2-(4-methylpiperazin-1-yl)phenyl]-propylamide;
 N-benzyl-N-methyl-3-[2-(4-methylpiperazin-1-yl)phenyl]-propylamide; and
 N-benzyl-3-[2-[(2-dimethylaminoethyl)-methylamino]phenyl]-propylamide.
 10 N-(4-chlorobenzyl)-3-[2-(4-methylpiperazin-1-yl)-4-(piperidine-1-carbonyl)phenyl]-acrylamide; and
 3-[5-fluoro-2-(4-methylpiperazin-1-yl)phenyl]-1-(2-phenylpiperidin-1-yl)-prop-2-ene-1-one.

[0022] The present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition selected from hypertension, depression, generalized anxiety disorder, phobias (e.g., agoraphobia, social phobia and simple phobias), posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation, eating disorders (e.g., anorexia nervosa and bulimia nervosa), obesity, chemical dependencies (e.g., addictions to alcohol, cocaine, heroin, phenobarbital, nicotine and benzodiazepines), cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders (e.g., dementia, amnestic disorders, and age-related cognitive decline (ARCD)), Parkinson's diseases (e.g., dementia in Parkinson's disease, neuroleptic-induced parkinsonism and tardive dyskinesias), endocrine disorders (e.g., hyperprolactinaemia), vasospasm (particularly in the cerebral vasculature), cerebellar ataxia, gastrointestinal tract disorders involving changes in motility and secretion, and chronic paroxysmal hemicrania and headache associated with vascular disorders in a mammal, preferably a human, comprising an amount of a compound of the formula I or a pharmaceutically acceptable salt thereof effective in treating or preventing such disorder or condition and a pharmaceutically acceptable carrier.

[0023] The present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition that can be treated or prevented by enhancing serotonergic neurotransmission in a mammal, preferably a human, comprising an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such disorder or condition and a pharmaceutically acceptable carrier. Examples of such disorders and conditions are those enumerated in the preceding paragraph.

[0024] The present invention also relates to a method for treating or preventing a disorder or condition selected from hypertension, depression, generalized anxiety disorder, phobias (e.g., agoraphobia, social phobia and simple phobias), posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation, eating disorders (e.g., anorexia nervosa and bulimia nervosa), obesity, chemical dependencies (e.g., addictions to alcohol, cocaine, heroin, phenobarbital, nicotine and benzodiazepines), cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders (e.g., dementia, amnestic disorders, and age-related cognitive decline (ARCD)), Parkinson's diseases (e.g., dementia in Parkinson's disease, neuroleptic-induced parkinsonism and tardive dyskinesias), endocrine disorders (e.g., hyperprolactinaemia), vasospasm (particularly in the cerebral vasculature), cerebellar ataxia, gastrointestinal tract disorders involving changes in motility and secretion, and chronic paroxysmal hemicrania and headache associated with vascular disorders in a mammal, preferably a human, comprising administering to a mammal in need of such treatment or prevention an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in treating or preventing such disorder or condition.

[0025] The present invention also relates to a method for treating or preventing a disorder or condition that can be treated or prevented by enhancing serotonergic neurotransmission in a mammal, preferably a human, comprising administering to a mammal in need of such treatment or prevention an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in treating or preventing such disorder or condition.

[0026] The present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition selected from hypertension, depression, generalized anxiety disorder, phobias (e.g., agoraphobia, social phobia and simple phobias), posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation, eating disorders (e.g., anorexia nervosa and bulimia nervosa), obesity, chemical dependencies (e.g., addictions to alcohol, cocaine, heroin, phenobarbital, nicotine and benzodiazepines), cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders (e.g., dementia, amnestic disorders, and age-related cognitive decline (ARCD)), Parkinson's diseases (e.g., dementia in Parkinson's disease, neuroleptic-induced parkinsonism and tardive dyskinesias), endocrine disorders (e.g., hyperprolactinaemia), vasospasm (particularly in the cerebral vasculature), cerebellar ataxia, gastrointestinal tract disorders involving changes in motility and secretion, and chronic paroxysmal hemicrania and headache associated with vascular disorders in a mammal, preferably a human, comprising a serotonin receptor antagonizing or agonizing effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0027] The present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition that can be treated or prevented by enhancing serotonergic neurotransmission in a mammal, preferably a

human, comprising a serotonin receptor antagonizing or agonizing effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

[0028] The present invention also relates to a method for treating or preventing a disorder or condition selected from hypertension, depression, generalized anxiety disorder, phobias (e.g., agoraphobia, social phobia and simple phobias), posttraumatic stress syndrome, avoidant personality disorder, sexual dysfunction (e.g., premature ejaculation), eating disorders (e.g., anorexia nervosa and bulimia nervosa), obesity, chemical dependencies (e.g., addictions to alcohol, cocaine, heroin, phenobarbital, nicotine and benzodiazepines), cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders (e.g., dementia, amnesia, amnestic disorders, and age-related cognitive decline (ARCD)), Parkinson's diseases (e.g., dementia in Parkinson's disease, neuroleptic-induced parkinsonism and tardive dyskinesias), endocrine disorders (e.g., hyperprolactinaemia), vasospasm (particularly in the cerebral vasculature), cerebellar ataxia, gastrointestinal tract disorders involving changes in motility and secretion, and chronic paroxysmal hemicrania and headache associated with vascular disorders in a mammal, preferably a human, comprising administering to a mammal requiring such treatment or prevention a serotonin receptor antagonizing or agonizing effective amount of a compound of the formula I or a pharmaceutically acceptable salt thereof.

[0029] The present invention also relates to a method for treating or preventing a disorder or condition that can be treated or prevented by enhancing serotonergic neurotransmission in a mammal, preferably a human, comprising administering to a mammal requiring such treatment or prevention a serotonin receptor antagonizing or agonizing effective amount of a compound of the formula I or a pharmaceutically acceptable salt thereof.

[0030] The present invention also relates to a pharmaceutical composition for treating or preventing a condition or disorder that can be treated or prevented by enhancing serotonergic neurotransmission in a mammal, preferably a human, comprising:

- a) a pharmaceutically acceptable carrier;
- b) a compound of the formula I or a pharmaceutically acceptable salt thereof; and
- c) a 5-HT re-uptake inhibitor, preferably sertraline, or a pharmaceutically acceptable salt thereof;

wherein the amount of the active compounds (i.e., the compound of formula I and the 5-HT re-uptake inhibitor) are such that the combination is effective in treating or preventing such disorder or condition.

[0031] The present invention also relates to a method for treating or preventing a disorder or condition that can be treated or prevented by enhancing serotonergic neurotransmission in a mammal, preferably a human, comprising administering to a mammal requiring such treatment or prevention:

- a) a compound of the formula I, defined above, or a pharmaceutically acceptable salt thereof; and
- b) a 5-HT re-uptake inhibitor, preferably sertraline, or a pharmaceutically acceptable salt thereof;

wherein the amounts of the active compounds (i.e., the compound of formula I and the 5-HT re-uptake inhibitor) are such that the combination is effective in treating or preventing such disorder or condition.

[0032] The present invention also relates to a method for treating or preventing a disorder or condition that can be treated or prevented by enhancing serotonergic neurotransmission in a mammal, preferably a human, comprising administering to said mammal requiring such treatment or prevention:


- a) a 5-HT_{1A} antagonist or a pharmaceutically acceptable salt thereof; and
- b) a 5-HT_{1D} antagonist or a pharmaceutically acceptable salt thereof;

wherein the amounts of each active compound (i.e., the 5-HT_{1A} antagonist and the 5-HT_{1D} antagonist) are such that the combination is effective in treating or preventing such disorder or condition.

[0033] "Enhanced serotonergic neurotransmission," as used herein, refers to increasing or improving the neuronal process whereby serotonin is released by a pre-synaptic cell upon excitation and crosses the synapse to stimulate or inhibit the post-synaptic cell.

[0034] "Chemical dependency," as used herein, means an abnormal craving or desire for, or an addiction to a drug. Such drugs are generally administered to the affected individual by any of a variety of means of administration, including oral, parenteral, nasal or by inhalation. Examples of chemical dependencies treatable by the methods of the present invention are dependencies on alcohol, nicotine, cocaine, heroin, phenobarbital, and benzodiazepines (e.g., Valium (trademark)). "Treating a chemical dependency," as used herein, means reducing or alleviating such dependency.

[0035] Sertraline, (1 S-cis)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine, as used herein has the chemical formula C₁₇H₁₇NCl₂ and the following structural formula



Its synthesis is described in United States Patent 4,536,518, assigned to Pfizer Inc. Sertraline hydrochloride is useful as an antidepressant and anorectic agent, and is also useful in the treatment of depression, chemical dependencies, anxiety obsessive compulsive disorders, phobias, panic disorder, post traumatic stress disorder, and premature ejaculation.

20

Detailed Description of the Invention

25 [0036] Compounds of the formula I may be prepared according to the following reaction Schemes and discussion. Unless otherwise indicated, g, m, p, q, R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹⁰, R¹¹, R¹², G¹, G², G³, G⁴, G⁵, E and X and XXIV in the reaction Schemes and discussions that follow are as defined above.

30

35

40


45

50

55

SCHEME 1


5



10

III


15



20

II

25



30

II

35


I

40

50

55

SCHEME 2



SCHEME 3

5

10

15

20

25

30


35

40


45

50


55




XIV



XVII

(R¹=G²)

SCHEME 4




[0037] Scheme 1 refers to the preparation of compounds of the formula I from compounds of the formula III. Compounds of the formula III are commercially available or can be made by methods well known to those of ordinary skill in the art.

[0038] Scheme 1 illustrates a method of synthesizing compounds of the formula I, wherein R¹ is a group of the formula G¹, G³, G⁴ or G⁵. Referring to Scheme 1, a compound of the formula III, wherein Q is a suitable leaving group (e.g. chloro, fluoro, bromo, mesylate, tosylate, etc.), is reacted with a compound of the formula R¹H, wherein R¹ is a group of the formula G¹, G³, G⁴ or G⁵, in the presence of a base, to form the corresponding compound of formula II. This reaction is generally carried out at a temperature from about 0°C to about 140°C for about 1 hour to about 5 days, preferably at about 25°C for about 3 days, in a polar solvent such as dimethyl sulfoxide (DMSO), N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMA) or N-methyl-2-pyrrolidinone (NMP), preferably DMF. Suitable bases include anhydrous sodium carbonate (Na₂CO₃), potassium carbonate (K₂CO₃), sodium hydroxide (NaOH) and potassium carbonate (K₂CO₃), as well as amines such as pyrrolidine, triethylamine and pyridine. Anhydrous potassium carbonate is preferred.

[0039] Compounds of formula II can be converted into compounds of the formula I by subjecting them to an aldol condensation or a Wittig reaction. For example, in the case of an aldol condensation, a compound of the formula II can be reacted with a compound of the formula

5




10

in the presence of a base, to form an aldol intermediate of the formula

15

20




25

which may be isolated or converted directly in the same reaction step to a compound of the formula I, wherein the dashed line is a double bond, by the loss of water. The degree of completion for the conversion of compounds of the formula II to the aldol product of formula I may be assessed using one or more analytical techniques, such as thin layer chromatography (tlc) or mass spectrometry. In some instances it may be possible or desirable to isolate the intermediate of formula V. In such case, the compound of formula V may be converted into the compound of formula I by the elimination of water using techniques which are familiar to those skilled in the art, for example, by heating to the reflux temperature a solution of the compound of formula V in a solvent such as benzene, toluene or xylene, in the presence of a catalytic amount of benzene- or p-toluenesulfonic acid with provision for the removal of the water generated. Such water removal techniques may involve the use of molecular sieves or a Dean-Stark trap to isolate the water created as an azeotrope with the solvent. The aldol reaction is typically carried out in a polar solvent such as DMSO, DMF, tetrahydrofuran (THF), methanol or ethanol, at a temperature from about -25°C to about 80°C. Preferably, this reaction is carried out in THF at about 25°C. Suitable bases for use in the aldol formation step include potassium carbonate (K₂CO₃), sodium carbonate (Na₂CO₃), sodium hydride (NaH), pyrrolidine and piperidine. Sodium hydride is preferred. Aldol condensations are described in "Modern Synthetic Reactions," Herbert O. House, 2d. Edition, W.A. Benjamin, Menlo Park, California, 629-682 (1972).

[0040] Alternatively, the compound of formula IV (i.e., a compound of formula IVa wherein "L" is hydrogen) can be converted into a compound of the formula I by means of a Wittig olefination, as described in Helvetica Chimica Acta, 46, 1580 (1953), and depicted below.

50

55

IVa $L = H$


XII

XI $L = (\text{e.g., Br})$

The compound of formula IVa can be converted into the corresponding bromide of formula XI using standard bromination conditions, followed by treatment with triphenylphosphine in anhydrous THF to form the intermediate of formula XII. The compound of formula XII can then be treated with a strong base (e.g., aqueous Na_2CO_3) to generate the corresponding phosphonium ylide, which can then be reacted with the appropriate intermediate of formula II to produce compounds of general formula I. This transformation is described in A. Maercker, Organic Reactions, 1965, 14, 270. [0041] Compounds of the formula I wherein the dashed line represents a single carbon-carbon bond may be prepared by hydrogenating the corresponding compounds wherein the dashed line represents a double carbon-carbon bond, using standard techniques that are well known to those skilled in the art. For example, reduction of the double bond may be effected with hydrogen gas (H_2), using catalysts such as palladium on carbon (Pd/C), palladium on barium sulfate (Pd/BaSO_4), platinum on carbon (Pt/C), or tris(triphenylphosphine) rhodium chloride (Wilkinson's catalyst), in an appropriate solvent such as methanol, ethanol, THF, dioxane or ethyl acetate, at a pressure from about 1 to about 5 atmospheres and a temperature from about 10°C to about 60°C, as described in Catalytic Hydrogenation in Organic Synthesis, Paul Rylander, Academic Press Inc., San Diego, 1979, pp. 31-63. The following conditions are preferred: Pd on carbon, methanol at 25°C and 50 psi of hydrogen gas pressure. This method also provides for introduction of hydrogen isotopes (i.e., deuterium, tritium) by replacing $^1\text{H}_2$ with $^2\text{H}_2$ or $^3\text{H}_2$ in the above procedure. [0042] An alternative procedure employing the use of reagents such as ammonium formate and Pd/C in methanol at the reflux temperature under an inert atmosphere (e.g., nitrogen or argon gas) is also effective in reducing the carbon-carbon double bond of compounds of the formula I. Another alternative method involves selective reduction of the carbon-carbon bond. This can be accomplished using samarium and iodine or samarium iodide (SmI_2) in methanol or ethanol at about room temperature, as described by R. Yanada et. al., Synlett., pp 4434 (1995). [0043] The starting materials of the formulas III and IV are either commercially available or known in the art. For example, compounds of formula III in which R^2 is hydrogen are readily available from commercial sources or may be prepared using procedures disclosed in the chemical literature. They may also be prepared from the corresponding carboxylic acids or esters (i.e., formula III) wherein $R^2 = \text{OH}$ or O-alkyl , which are commercially available. These acids or esters can be reduced to the corresponding alcohols of formula XIII, depicted below, wherein Q is defined as for formula III, using one or more of a variety of reducing agents and conditions, depending upon the nature of the substituents Q and X.


50

55



15 Such reducing agents include sodium borohydride (NaBH_4), sodium cyanoborohydride ($\text{NaC}(\text{N})\text{BH}_3$), lithium aluminum hydride (LiAlH_4) and borane in THF ($\text{BH}_3\text{-THF}$) in solvents such as methanol, ethanol, THF, diethyl ether and dioxane. Oxidation of the alcohol of formula XIII to the corresponding aldehyde of formula II may be accomplished using a selective oxidizing agent such as Jones reagent (hydrogen chromate (H_2CrO_4)), pyridinium chlorochromate (PCC) or manganese dioxide (MnO_2). References for such conversions are readily available (e.g., K.B. Wiberg, Oxidation in Organic Chemistry, Part A, Academic Press Inc, N.Y., 69-72 (1965)).

[0044] The compounds of formula R¹H used in the preparation of intermediates of the formula III are readily available or may be prepared using standard methods of organic synthesis known to those skilled in the art and adapted from procedures disclosed in the chemical literature. For example, the preparation of compounds of the formula R¹H, wherein R¹ is G¹, may be accomplished using the following reaction sequence, beginning with commercially available N-tert-butoxycarbonyl piperazine (VI):



45 Alkylation of the compound of formula VI with a compound of the formula R^6Y wherein Y is a leaving group, and is defined as Q is defined above and R^6 is (C_1 - C_6)alkyl, aryl-(C_2 - C_4)alkyl wherein the aryl moiety is phenyl or naphthyl, or heteroaryl-(CH_2) q , wherein q is zero, one, two, three or four, and the heteroaryl moiety is selected from pyridyl, pyrimidyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl, and benzisothiazolyl, in the presence of an acid scavenger (e.g., sodium bicarbonate ($NaHCO_3$), potassium bicarbonate ($KHCO_3$), sodium carbonate (Na_2CO_3) or potassium carbonate (K_2CO_3)), in a polar solvent such as acetone at a temperature of about 10°C to about the reflux temperature of the solvent, will yield the intermediate of formula VII. Removal of the tert-butoxycarbonyl group can be accomplished using acidic conditions, e.g., HBr in acetic acid or trifluoroacetic acid until the reaction is judged to be complete.

[0045] Compounds of the formula II wherein R¹ is tetrahydropyridine or piperidine and R² is hydrogen can be prepared from 2-bromobenzaldehyde, which is commercially available, as depicted in Scheme 2. Referring to Scheme 2, the compound of formula III is first converted into a protected aldehyde or ketone of the formula XIV, wherein P represents the entire protected aldehyde or ketone moiety, using methods well known in the art. For example, the 1,3-dioxolane derivative of the aldehyde may be prepared according to the method described by J.E. Cole *et al.*, *J. Chem. Soc.*, 244 (1962), by refluxing a solution of the aldehyde of formula III and 1,3-propanediol in anhydrous benzene with a catalytic amount of p-toluenesulfonic acid. When R² of formula III is not hydrogen, the ketone can be protected using an appropriate protecting group. Appropriate protecting groups can be chosen from many such groups based on the presence and nature of the substituent X. Examples of suitable protecting groups may be found in T.W. Greene, *Protecting*


Groups in Organic Synthesis, John Wiley & Sons, New York, 1981. The most preferred protecting groups are those that are resistant to catalytic hydrogenation (e.g., 1, 3-dioxolane), which would therefore allow for the subsequent reduction, if required, of the carbon-carbon double bond of the tetrahydropyridines of formula XVI A.

[0046] Compounds of the formula XIV can then be treated with vinylstannanes of the formula

5

10

15



XV

20 (1-BOC-4-trimethylstannyl-1,2,5,6-tetrahydropyridine) (wherein BOC refers to tert-butyloxycarbonyl), in the presence of a catalyst, to form the corresponding compound of formula XVI A. Palladium is the preferred catalyst (for example, $(C_6H_5)_3Pd$ or $Pd_2(dba)_3$), wherein dba refers to dibenzylideneacetone. This reaction may be carried out as described in "Palladium-catalyzed Vinylation of Organic Halides" in Organic Reactions, 27, 345-390, W.G. Dauben, Ed., John Wiley & Sons, Inc., New York, New York, (1982).

25 [0047] Compounds of formula II where R^1 is piperidine (G^2) can be prepared by catalytic hydrogenation of the tetrahydropyridine of formula XVI A from the previous paragraph using standard methods known in the art, generally using palladium on carbon as the catalyst, to form the corresponding compounds of formula XVI B. This reaction is typically performed in an inert solvent, such as ethanol or ethyl acetate, either with or without a protic acid such as acetic acid or hydrochloric acid (HCl). Acetic acid is preferred. The protecting groups on G^2 (e.g., BOC) can be removed using one


30 or more of the techniques described in Greene, referred to above, for example, stirring the compound of formula XVI in ethyl acetate and 3 molar hydrochloric acid at about room temperature for about 30 minutes. The protecting group for the aldehyde or ketone, P, can be converted into the unprotected ketone or aldehyde of the formula $-C(=O)R^2$ using one or more of the techniques described in Greene, for example, stirring a solution of the compound of formula XVI in THF and 5% hydrochloric acid at room temperature for 20 hours.

35 [0048] Compounds of the formula XIV from the previous reaction scheme may also be treated with alkylolithium reagents, for example butyllithium, sec-butyllithium or tert-butyllithium, preferably butyllithium in an inert solvent, as shown in Scheme 3, to form the intermediate lithium anion of formula XVI I. Suitable solvents for this reaction include, for example, ether or tetrahydrofuran, preferably tetrahydrofuran. Reaction temperatures can range from about -110°C to about 0°C. The intermediate lithium anions of formula XVI I can then be further reacted with a suitable electrophile, selection of which depends on the presence and nature of the substituent. Suitable electrophiles for use in preparing compounds of the formula II wherein R^1 is a group of the formula G^2 include, for example, carbonyl derivatives or alkylating agents (e.g., 1-BOC-4-piperidone). In the case where an aldehyde or ketone is used as the electrophile, the hydroxy group must be removed from the intermediate of formula XVI I, as depicted below, in order to form the corresponding compound of formula II.

45

50

55



This step may be accomplished by one of several standard methods known in the art. For example, a thiocarbonyl derivative such as a xanthate may be prepared and removed by free radical processes, both of which are known to those skilled in the art. Alternatively, the hydroxyl group may be removed by reduction with a hydride source such as triethylsilane under acidic conditions, using, for example, trifluoroacetic acid or boron trifluoride. The reduction reaction can be performed neat or in a solvent such as methylene chloride. A further alternative would be to first convert the hydroxyl group to a suitable leaving group, such as tosylate or chloride, using standard methods known in the art, and then to remove the leaving group with a nucleophilic hydride, such as, for example, lithium aluminum hydride. The latter reaction is typically performed in an inert solvent such as ether or tetrahydrofuran. Also, a reducing agent may be used to reductively remove the benzylic substituent. Suitable reducing agents include, for example, Raney nickel in ethanol and sodium or lithium in liquid ammonia. Another alternative method for removing the hydroxyl group is to first dehydrate the alcohol of formula XVIII to an olefin, of formula XVI (i.e. see Scheme 2), with a reagent such as Burgess salt (J. Org. Chem., 38, 26 (1973)) and then to catalytically hydrogenate the double bond under standard conditions with a catalyst such as palladium on carbon. The alcohol may also be dehydrated to the olefin by treatment with acids such as p-toluenesulfonic acid.

[0049] Compounds of the formula II, wherein R^1 is G^2 and R^6 is hydrogen, can be converted into the corresponding compounds of the formula II wherein R^1 is G^2 and R^5 is other than hydrogen, by reacting them with a compound of the formula R^6Y , as described above for preparing compounds of the formula VII.

[0050] Compounds of formula I, wherein R^6 is other than hydrogen, can also be prepared from compounds of the formula XX, according to the methods of Scheme 4. Compounds of the formula XX are commercially available or can be made by methods well known to those of ordinary skill in the art. Referring to Scheme 4, a compound of the formula XX is converted to a compound of the formula XXI by reaction with a compound of the formula R^1H , wherein R^1 is G^1 , G^3 , G^4 or G^5 , in the presence of a base. This reaction is generally carried out at a temperature from about 0°C to about 140°C for about 1 hour to about 5 days, preferably at about 25°C for about 3 days, in a polar solvent such as dimethyl sulfoxide (DMSO), N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMA) or N-methyl-2-pyrrolidinone (NMP), preferably DMF. Suitable bases include anhydrous sodium carbonate (Na_2CO_3), potassium carbonate (K_2CO_3), sodium hydroxide (NaOH) and potassium hydroxide (KOH), as well as amines such as pyrrolidine, triethylamine and pyridine. Anhydrous potassium carbonate is preferred.


[0051] Compounds of the formula XXI are reduced to compounds of the formula XXII in the presence of a reducing agent in a reaction inert solvent. Suitable reducing agents include using hydrogen gas in the presence of a catalyst, such as palladium on carbon, Raney Nickel and the like. Suitable reaction inert solvents include methanol, ethanol or ethyl acetate. The aforesaid reaction may be performed at an initial pressure of from about one to about four atmos-

phers and at a temperature of about 0°C to about 60°C. Typically, the reaction is conducted with methanol as the solvent and with about three atmospheres of hydrogen gas pressure at room temperature for about 0.5 to 1.0 hrs.

5 [0052] Compounds of the formula XXII are converted into compounds of the formula I via a diazonium intermediate of the formula XXIII. This conversion, a so called Heck reaction, can be accomplished as described in several references, including, for example, those by Sengupta and Bhattacharyya in Tetrahedron Letters, 36 (25), 4475-4478 (1995), and by Kikukawa et al. in Chemistry Letters, 551-552 (1980). Specifically, an amino compound of the formula XXII may be treated with a diazotizing reagent such as NaNO₂, or an alkyl nitrite such as tert-butyl nitrite, which is capable of transforming the amino compound of XXII to a diazonium salt of the formula XXIII. The diazonium salt may be isolated, but more conveniently it is prepared in situ and then treated with an acrylamide of formula

10

15



20 in the presence of a catalytic amount of a palladium complex such as palladium (II) acetate or bis(dibenzylideneacetone) palladium (0), palladium (II) acetate being preferred. The reaction is carried out in an inert solvent such as methanol, ethanol or acetic acid at a temperature of about 0 °C to about the reflux temperature of the solvent used and at atmospheric pressure for a period of about 15 minutes to about 4 days.

25 [0053] The compounds of formula XXIV are readily prepared from commercially available starting materials by methods and procedures disclosed in the scientific literature. For example, reaction of an acid chloride of formula R²-CH=CR⁵-COCl with an amine of the general formula HNR³R⁴ in an inert solvent such as chloroform, methylene chloride, THF or diethyl ether and in the presence of an acid scavenger such as triethylamine or pyridine are generally useful for the preparation of the amide intermediate.

30 [0054] Compounds of the formula I, wherein the dashed line is a double bond, can be reduced to form a compound of formula I, wherein the dashed line represents a single bond by the methods described in Scheme 1.

35 [0055] Unless indicated otherwise, the pressure of each of the above reactions is not critical. Generally, the reactions will be conducted at a pressure of about one to about three atmospheres, preferably at ambient pressure (about one atmosphere).

40 [0056] The compounds of the formula I which are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate a compound of the formula I from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent, and subsequently convert the free base to a pharmaceutically acceptable acid addition salt. The acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is obtained.

45 [0057] The acids which are used to prepare the pharmaceutically acceptable acid addition salts of the base compounds of this invention are those which form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate or bisulfate, phosphate or acid phosphate, acetate, lactate, citrate or acid citrate, tartrate or bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate and pamoate [i.e., 1,1'-methylene-bis-(2-hydroxy-3-naphthoate)] salts.

50 [0058] Those compounds of the formula I which are also acidic in nature, e.g., where R³ includes a COOH or tetrazole moiety, are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include the alkali metal or alkaline-earth metal salts and particularly, the sodium and potassium salts. These salts are all prepared by conventional techniques. The chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the herein described acidic

55 compounds of formula I. These non-toxic base salts include those derived from such pharmacologically acceptable cations as sodium, potassium, calcium and magnesium, etc. These salts can easily be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively, they may also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before. In either case, stoichiometric

quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum product yields.

[0059] Compounds of the formula I and their pharmaceutically acceptable salts (hereinafter also referred to, collectively, as "the active compounds") are useful psychotherapeutics and are potent agonists and/or antagonists of the serotonin 1A (5-HT_{1A}) and/or serotonin 1D (5-HT_{1D}) receptors. The active compounds are useful in the treatment of hypertension, depression, generalized anxiety disorder, phobias (e.g., agoraphobia, social phobia and simple phobias), posttraumatic stress syndrome, avoidant personality disorder, sexual dysfunction (e.g., premature ejaculation), eating disorders (e.g., anorexia nervosa and bulimia nervosa), obesity, chemical dependencies (e.g., addictions to alcohol, cocaine, heroin, phenobarbital, nicotine and benzodiazepines), cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders (e.g., dementia, amnestic disorders, and age-related cognitive decline (ARCD)), Parkinson's diseases (e.g., dementia in Parkinson's disease, neuroleptic-induced parkinsonism and tardive dyskinésias), endocrine disorders (e.g., hyperprolactinaemia), vasospasm (particularly in the cerebral vasculature), cerebellar ataxia, gastrointestinal tract disorders involving changes in motility and secretion, and chronic paroxysmal hemicrania and headache associated with vascular disorders. These compounds are also useful as vasodilators.

[0060] The affinities of the compounds of this invention for the various serotonin-1 receptors can be determined using standard radioligand binding assays as described in the literature. The 5-HT_{1A} affinity can be measured using the procedure of Hoyer et al. (Brain Res., 1986, 376, 85). The 5-HT_{1D} affinity can be measured using the procedure of Heuring and Peroutka (J. Neurosci., 1987, 7, 894).

[0061] The *in vitro* activity of the compounds of the present invention at the 5-HT_{1D} binding site may be determined according to the following procedure. Bovine caudate tissue is homogenized and suspended in 20 volumes of a buffer containing 50 mM TRIS•hydrochloride (tris[hydroxymethyl]aminomethane hydrochloride) at a pH of 7.7. The homogenate is then centrifuged at 45,000G for 10 minutes. The supernatant is then discarded and the resulting pellet resuspended in approximately 20 volumes of 50 mM TRIS•hydrochloride (HCl) buffer at pH 7.7. This suspension is then pre-incubated for 15 minutes at 37°C, after which the suspension is centrifuged again at 45,000G for 10 minutes and the supernatant discarded. The resulting pellet (approximately 1 gram) is resuspended in 150 ml of a buffer of 15 mM TRIS•hydrochloride (HCl) containing 0.01 percent ascorbic acid with a final pH of 7.7 and also containing 10 µM pargyline and 4 mM calcium chloride (CaCl₂). The suspension is kept on ice at least 30 minutes prior to use.

[0062] The inhibitor, control or vehicle is then incubated according to the following procedure. To 50 µl of a 20 percent dimethylsulfoxide (DMSO)/80 percent distilled water solution is added 200 µl of tritiated 5-hydroxytryptamine (2 nM) in a buffer of 50 mM TRIS•hydrochloride containing 0.01 percent ascorbic acid at pH 7.7 and also containing 10 µM pargyline and 4 µM calcium chloride, plus 100 nM of 8-hydroxy-DPAT (dipropylaminotetraline) and 100 nM of mesulergine. To this mixture is added 750 µl of bovine caudate tissue, and the resulting suspension is vortexed to ensure a homogenous suspension. The suspension is then incubated in a shaking water bath for 30 minutes at 25°C. After incubation is complete, the suspension is filtered using glass fiber filters (e.g., Whatman GF/B-filters™). The pellet is then washed three times with 4 ml of a buffer of 50 mM TRIS•hydrochloride at pH 7.7. The pellet is then placed in a scintillation vial with 5 ml of scintillation fluid (aqua-sol 2™) and allowed to sit overnight. The percent inhibition can be calculated for each dose of the compound. An IC₅₀ value can then be calculated from the percent inhibition values.

[0063] The activity of the compounds of the present invention for 5-HT_{1A} binding ability can be determined according to the following procedure. Rat brain cortex tissue is homogenized and divided into samples of 1 gram lots and diluted with 10 volumes of 0.32 M sucrose solution. The suspension is then centrifuged at 900G for 10 minutes and the supernate separated and re-centrifuged at 70,000G for 15 minutes. The supernate is discarded and the pellet re-suspended in 10 volumes of 15 mM TRIS•hydrochloride at pH 7.5. The suspension is allowed to incubate for 15 minutes at 37°C. After pre-incubation is complete, the suspension is centrifuged at 70,000G for 15 minutes and the supernate discarded. The resulting tissue pellet is resuspended in a buffer of 50 mM TRIS•hydrochloride at pH 7.7 containing 4 mM of calcium chloride and 0.01 percent ascorbic acid. The tissue is stored at -70°C until ready for an experiment. The tissue can be thawed immediately prior to use, diluted with 10 µM pargyline and kept on ice.

[0064] The tissue is then incubated according to the following procedure. Fifty microliters of control, inhibitor, or vehicle (1 percent DMSO final concentration) is prepared at various dosages. To this solution is added 200 µl of tritiated DPAT at a concentration of 1.5 nM in a buffer of 50 mM TRIS•hydrochloride at pH 7.7 containing 4 mM calcium chloride, 0.01 percent ascorbic acid and pargyline. To this solution is then added 750 µl of tissue and the resulting suspension is vortexed to ensure homogeneity. The suspension is then incubated in a shaking water bath for 30 minutes at 37°C. The solution is then filtered, washed twice with 4 ml of 10 mM TRIS•hydrochloride at pH 7.5 containing 154 mM of sodium chloride. The percent inhibition is calculated for each dose of the compound, control or vehicle. IC₅₀ values are calculated from the percent inhibition values.

[0065] The compounds of formula I of the present invention described in the following Examples were assayed for 5-HT_{1A} and 5-HT_{1D} affinity using the aforementioned procedures. All such compounds exhibited IC₅₀'s less than 0.60 µM for 5-HT_{1D} affinity and IC₅₀'s less than 1.0 µM for 5-HT_{1A} affinity.

[0066] The agonist and antagonist activities of the compounds of the invention at 5-HT_{1A} and 5-HT_{1D} receptors can be determined using a single saturating concentration according to the following procedure. Male Hartley guinea pigs are decapitated and 5-HT_{1A} receptors are dissected out of the hippocampus, while 5-HT_{1D} receptors are obtained by slicing at 350 mm on a McIlwain tissue chopper and dissecting out the substantia nigra from the appropriate slices.

5 The individual tissues are homogenized in 5 mM HEPES buffer containing 1 mM EGTA (pH 7.5) using a hand-held glass-Teflon® homogenizer and centrifuged at 35,000 x g for 10 minutes at 4°C. The pellets are resuspended in 100 mM HEPES buffer containing 1 mM EGTA (pH 7.5) to a final protein concentration of 20 mg (hippocampus) or 5 mg (substantia nigra) of protein per tube. The following agents are added so that the reaction mix in each tube contain 2.0 mM MgCl₂, 0.5 mM ATP, 1.0 mM cAMP, 0.5 mM IBMX, 10 mM phosphocreatine, 0.31 mg/mL creatine phosphokinase, 100 μM GTP and 0.5-1 microcuries of [³²P]-ATP (30 Ci/mmol: NEG-003 - New England Nuclear). Incubation is initiated by the addition of tissue to siliconized microfuge tubes (in triplicate) at 30°C for 15 minutes. Each tube receives 20 μL tissue, 10 μL drug or buffer (at 10X final concentration), 10 μL 32 nM agonist or buffer (at 10X final concentration), 20 μL forskolin (3 μM final concentration) and 40 μL of the preceding reaction mix. Incubation is terminated by the addition of 100 μL 2% SDS, 1.3 mM cAMP, 45 mM ATP solution containing 40,000 dpm [³H]-cAMP (30 Ci/mmol: NET-275 - New England Nuclear) to monitor the recovery of cAMP from the columns. The separation of [³²P]-ATP and [³H]-cAMP is accomplished using the method of Salomon *et al.*, *Analytical Biochemistry*, 1974, **58**, 541-548. Radioactivity is quantified by liquid scintillation counting. Maximal inhibition is defined by 10 μM (R)-8-OH-DPAT for 5-HT_{1A} receptors, and 320 nM 5-HT for 5-HT_{1D} receptors. Percent inhibitions by the test compounds are then calculated in relation to the inhibitory effect of (R)-8-OH-DPAT for 5-HT_{1A} receptors or 5-HT for 5-HT_{1D} receptors. The reversal of agonist induced

20 inhibition of forskolin-stimulated adenylate cyclase activity is calculated in relation to the 32 nM agonist effect.

[0067] The compounds of the invention can be tested for *in vivo* activity for antagonism of 5-HT_{1D} agonist-induced hypothermia in guinea pigs according to the following procedure.

25 [0068] Male Hartley guinea pigs from Charles River, weighing 250-275 grams on arrival and 300-600 grams at testing, serve as subjects in the experiment. The guinea pigs are housed under standard laboratory conditions on a 7 a.m. to 7 p.m. lighting schedule for at least seven days prior to experimentation. Food and water are available *ad libitum* until the time of testing.

30 [0069] The compounds of the invention can be administered as solutions in a volume of 1 ml/kg. The vehicle used is varied depending on compound solubility. Test compounds are typically administered either sixty minutes orally (p. o.) or 0 minutes subcutaneously (s.c.) prior to the 5-HT_{1D} agonist, which is administered at a dose of 5.6 mg/kg, s.c.. Before a first temperature reading is taken, each guinea pig is placed in a clear plastic shoe box containing wood chips and a metal grid floor and allowed to acclimate to the surroundings for 30 minutes. Animals are then returned to the same shoe box after each temperature reading. Prior to each temperature measurement each animal is firmly held with one hand for a 30-second period. A digital thermometer with a small animal probe is used for temperature measurements. The probe is made of semi-flexible nylon with an epoxy tip. The temperature probe is inserted 6 cm. into the rectum and held there for 30 seconds or until a stable recording is obtained. Temperatures are then recorded.

35 [0070] In p.o. screening experiments, a "pre-drug" baseline temperature reading is made at -90 minutes, the test compound is given at -60 minutes and an additional -30 minute reading is taken. The 5-HT_{1D} agonist is then administered at 0 minutes and temperatures are taken 30, 60, 120 and 240 minutes later.

40 [0071] In subcutaneous screening experiments, a pre-drug baseline temperature reading is made at -30 minutes. The test compound and 5-HT_{1D} agonists are given concurrently and temperatures are taken at 30, 60, 120 and 240 minutes later.

[0072] Data are analyzed with two-way analysis of variants with repeated measures in Newman-Keuls post hoc analysis.

45 [0073] The active compounds of the invention can be evaluated as anti-migraine agents by testing the extent to which they mimic sumatriptan in contracting the dog isolated saphenous vein strip [P.P.A. Humphrey *et al.*, *Br. J. Pharmacol.*, **94**, 1128 (1988)]. This effect can be blocked by methiothepin, a known serotonin antagonist. Sumatriptan is known to be useful in the treatment of migraine and produces a selective increase in carotid vascular resistance in the anesthetized dog. The pharmacological basis of sumatriptan efficacy has been discussed in W. Fenwick *et al.*, *Br. J. Pharmacol.*, **96**, 83 (1989).

50 [0074] The serotonin 5-HT₁ agonist activity can be determined by the *in vitro* receptor binding assays, as described for the 5-HT_{1A} receptor using rat cortex as the receptor source and [³H]-8-OH-DPAT as the radioligand [D. Hoyer *et al.* *Eur. J. Pharm.*, **118**, 13 (1985)] and as described for the 5-HT_{1D} receptor using bovine caudate as the receptor source and [³H]serotonin as the radioligand [R.E. Heuring and S.J. Peroutka, *J. Neuroscience*, **7**, 894 (1987)]. Of the active compounds tested, all exhibited an IC₅₀ in either assay of 1 μM or less.

55 [0075] The compounds of formula I may advantageously be used in conjunction with one or more other therapeutic agents, for instance, different antidepressant agents such as tricyclic antidepressants (e.g., amitriptyline, dothiepin, doxepin, trimipramine, butriptyline, clomipramine, desipramine, imipramine, iprindole, lofepramine, nortriptyline or protriptyline), monoamine oxidase inhibitors (e.g., isocarboxazid, phenelzine or tranylcyclopramine) or 5-HT re-uptake

inhibitors (e.g., fluvoxamine, sertraline, fluoxetine or paroxetine), and/or with antiparkinsonian agents such as dopa-
 5 ergic antiparkinsonian agents (e.g., levodopa, preferably in combination with a peripheral decarboxylase inhibitor e.g., benserazide or carbidopa, or with a dopamine agonist e.g., bromocriptine, lisdopride or pergolide). It is to be under-
 stood that the present invention covers the use of a compound of general formula (I) or a physiologically acceptable
 salt or solvate thereof in combination with one or more other therapeutic agents.

[0076] Compounds of the formula I and the pharmaceutically acceptable salts thereof, in combination with a 5-HT
 re-uptake inhibitor (e.g., fluvoxamine, sertraline, fluoxetine or paroxetine), preferably sertraline, or a pharmaceutically
 10 acceptable salt or polymorph thereof (the combination of a compound of formula I with a 5-HT re-uptake inhibitor is
 referred herein to as "the active combination"), are useful psychotherapeutics and may be used in the treatment or
 prevention of disorders the treatment or prevention of which is facilitated by enhanced serotonergic neurotransmission
 15 (e.g., hypertension, depression, generalized anxiety disorder, phobias, posttraumatic stress syndrome, avoidant per-
 sonality disorder, sexual dysfunction, eating disorders, obesity, chemical dependencies, cluster headache, migraine,
 pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders (e.g., dementia, amnestic
 20 disorders, and age-related cognitive decline (ARCD)), Parkinson's diseases (e.g., dementia in Parkinson's disease,
 neuroleptic-induced Parkinsonism and tardive dyskinesias), endocrine disorders (e.g., hyperprolactinaemia), vasos-
 25 spasm (particularly in the cerebral vasculature), cerebellar ataxia, gastrointestinal tract disorders involving changes in
 motility and secretion and chronic paroxysmal hemicrania and headache associated with vascular disorders.

[0077] Serotonin (5-HT) re-uptake inhibitors, preferably sertraline, exhibit positive activity against depression; chem-
 20 ical dependencies; anxiety disorders including panic disorder, generalized anxiety disorder, agoraphobia, simple pho-
 bias, social phobia, and post-traumatic stress disorder; obsessive-compulsive disorder; avoidant personality disorder
 and premature ejaculation in mammals, including humans, due in part to their ability to block the synaptosomal uptake
 of serotonin.

[0078] United States Patent 4,536,518 describes the synthesis, pharmaceutical composition and use of sertraline
 for depression and is hereby incorporated by reference in its entirety.

[0079] Activity of the active combination as antidepressants and related pharmacological properties can be deter-
 25 mined by methods (1)-(4) below, which are described in Koe, B. et al., Journal of Pharmacology and Experimental
Therapeutics, 226 (3), 686-700 (1983). Specifically, activity can be determined by studying (1) their ability to affect the
 efforts of mice to escape from a swim-tank (Porsolt mouse "behavior despair" test), (2) their ability to potentiate 5-hy-
 30 droxytryptophan-induced behavioral symptoms in mice *in vivo*, (3) their ability to antagonize the serotonin-depleting
 activity of p-chloroamphetamine hydrochloride in rat brain *in vivo*, and (4) their ability to block the uptake of serotonin,
 norepinephrine and dopamine by synaptosomal rat brain cells *in vitro*. The ability of the active combination to counteract
 35 reserpine hypothermia in mice *in vivo* can be determined according to the methods described in U.S. Pat. No. 4,029,731.

[0080] The compositions of the present invention may be formulated in a conventional manner using one or more
 40 pharmaceutically acceptable carriers. Thus, the active compounds of the invention may be formulated for oral, buccal,
 intranasal, parenteral (e.g., intravenous, intramuscular or subcutaneous) or rectal administration or in a form suitable
 45 for administration by inhalation or insufflation.

[0081] For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules
 40 prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pre-gelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato
 45 starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulphate). The tablets may be coated by
 methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions,
 syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle
 before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable ad-
 50 ditives such as suspending agents (e.g., sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying
 agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters or ethyl alcohol); and preservatives
 (e.g., methyl or propyl p-hydroxybenzoates or sorbic acid).

[0082] For buccal administration, the composition may take the form of tablets or lozenges formulated in conventional
 55 manner.

[0083] The active compounds of the invention may be formulated for parenteral administration by injection, including
 using conventional catheterization techniques or infusion. Formulations for injection may be presented in unit dosage
 form, e.g., in ampules or in multi-dose containers, with an added preservative. The compositions may take such forms
 as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulating agents such as sus-
 55 pending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for recon-
 stitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

[0084] The active compounds of the invention may also be formulated in rectal compositions such as suppositories
 or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.

[0085] For intranasal administration or administration by inhalation, the active compounds of the invention are con-

veniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant, *e.g.*, dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurized container or nebulizer may contain a solution or suspension of the active compound. Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.

5 [0086] A proposed dose of the active compounds of the invention for oral, parenteral or buccal administration to the average adult human for the treatment of the conditions referred to above (*e.g.*, migraine) is 0.1 to 200 mg of the active ingredient per unit dose which could be administered, for example, 1 to 4 times per day.

10 [0087] Aerosol formulations for treatment of the conditions referred to above (*e.g.*, migraine) in the average adult human are preferably arranged so that each metered dose or "puff" of aerosol contains 20 μ g to 1000 μ g of the compound of the invention. The overall daily dose with an aerosol will be within the range 100 μ g to 10 mg. Administration may be several times daily, for example 2, 3, 4 or 8 times, giving for example, 1, 2 or 3 doses each time.

15 [0088] In connection with the use of an active compound of this invention with a 5-HT re-uptake inhibitor, preferably sertraline, for the treatment of subjects possessing any of the above conditions, it is to be noted that these compounds may be administered either alone or in combination with pharmaceutically acceptable carriers by either of the routes previously indicated, and that such administration can be carried out in both single and multiple dosages. More particularly, the active combination can be administered in a wide variety of different dosage forms, *i.e.*, they may be combined with various pharmaceutically-acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders, sprays, aqueous suspension, injectable solutions, elixirs, syrups, and the like. Such carriers include solid diluents or fillers, sterile aqueous media and various non-toxic organic solvents, etc. Moreover, such oral pharmaceutical formulations can be suitably sweetened and/or flavored by means of various agents of the type commonly employed for such purposes. In general, the compounds of formula I are present in such dosage forms at 20 concentration levels ranging from about 0.5% to about 90% by weight of the total composition, *i.e.*, in amounts which are sufficient to provide the desired unit dosage and a 5-HT re-uptake inhibitor, preferably sertraline, is present in such dosage forms at concentration levels ranging from about 0.5% to about 90% by weight of the total composition, *i.e.*, in amounts which are sufficient to provide the desired unit dosage.

25 [0089] A proposed daily dose of an active compound of this invention in the combination formulation (a formulation containing an active compound of this invention and a 5-HT re-uptake inhibitor) for oral, parenteral, rectal or buccal administration to the average adult human for the treatment of the conditions referred to above is from about 0.01 mg to about 2000 mg, preferably from about 0.1 mg to about 200 mg of the active ingredient of formula I per unit dose which could be administered, for example, 1 to 4 times per day.

30 [0090] A proposed daily dose of a 5-HT re-uptake inhibitor, preferably sertraline, in the combination formulation for oral, parenteral or buccal administration to the average adult human for the treatment of the conditions referred to above is from about 0.1 mg to about 2000 mg, preferably from about 1 mg to about 200 mg of the 5-HT re-uptake inhibitor per unit dose which could be administered, for example, 1 to 4 times per day.

35 [0091] A preferred dose ratio of sertraline to an active compound of this invention in the combination formulation for oral, parenteral or buccal administration to the average adult human for the treatment of the conditions referred to above is from about 0.00005 to about 20,000, preferably from about 0.25 to about 2,000.

40 [0092] Aerosol combination formulations for treatment of the conditions referred to above in the average adult human are preferably arranged so that each metered dose or "puff" of aerosol contains from about 0.01 μ g to about 1000 μ g of the active compound of this invention, preferably from about 1 μ g to about 10 mg of such compound. Administration may be several times daily, for example 2, 3, 4 or 8 times, giving for example, 1, 2 or 3 doses each time.

45 [0093] Aerosol formulations for treatment of the conditions referred to above in the average adult human are preferably arranged so that each metered dose or "puff" of aerosol contains from about 0.01 mg to about 2000 mg of a 5-HT re-uptake inhibitor, preferably sertraline, preferably from about 1 mg to about 200 mg of sertraline. Administration may be several times daily, for example 2, 3, 4 or 8 times, giving for example, 1, 2 or 3 doses each time.

50 [0094] As previously indicated, a 5-HT re-uptake inhibitor, preferably sertraline, in combination with compounds of formula I are readily adapted to therapeutic use as antidepressant agents. In general, these antidepressant compositions containing a 5-HT re-uptake inhibitor, preferably sertraline, and a compound of formula I are normally administered in dosages ranging from about 0.01 mg to about 100 mg per kg of body weight per day of a 5-HT re-uptake inhibitor, preferably sertraline, preferably from about 0.1 mg. to about 10 mg per kg of body weight per day of sertraline; with from about 0.001 mg. to about 100 mg per kg of body weight per day of a compound of formula I, preferably from about 0.01 mg to about 10 mg per kg of body weight per day of a compound of formula I, although variations will necessarily occur depending upon the conditions of the subject being treated and the particular route of administration chosen.

55 [0095] The following Examples illustrate the preparation of the compounds of the present invention. Melting points are uncorrected. NMR data are reported in parts per million (δ) and are referenced to the deuterium lock signal from

the sample solvent (deuteriochloroform unless otherwise specified). Specific rotations were measured at room temperature using the sodium D line (589 nm). Commercial reagents were utilized without further purification. THF refers to tetrahydrofuran. DMF refers to N,N-dimethylformamide. Chromatography refers to column chromatography performed using 32-63 μ m silica gel and executed under nitrogen pressure (flash chromatography) conditions. Room or ambient temperature refers to 20-25°C. All non-aqueous reactions were run under a nitrogen atmosphere for convenience and to maximize yields. Concentration at reduced pressure implies the use of a rotary evaporator.

Example 1

3-[2-(4-Methylpiperazin-1-yl)phenyl]-2,N-diphenylacrylamide

[0096] To a mixture of 2-(4-methylpiperazin-1-yl)benzaldehyde (0.157 g, 0.77 mmol), 2,N-diphenylacetamide (0.162 g, 0.77 mmol), benzene (1.0 mL) and N,N-dimethylformamide (1.1 mL) was added anhydrous sodium methoxide (0.087 g, 1.62 mmol). Under a nitrogen atmosphere (N_2), the mixture was heated to 80°C for 16 hours, at which time another 46 mg of sodium methoxide ($NaOCH_3$) was added and heating continued at 130°C for 7 hours. The reaction was cooled to room temperature and was diluted with ethyl acetate ($EtOAc$), washed twice with 1N lithium chloride ($LiCl$), once with saturated aqueous sodium chloride, and dried over calcium sulfate ($CaSO_4$). After filtration, the crude product was absorbed onto 450 mg of silica gel and added to a 4.0 X 8 inch column packed with silica gel and ethyl acetate. Elution with ethyl acetate (200 mL) followed by 1% methanol: 99% ethyl acetate (100 mL) gave 35 mg of a light yellow oil which was crystallized from methylene chloride:hexanes to give the title product, 5 mg, as a yellow powder.

Mass spectrum: 398 (M^{+1})

1H -NMR ($CDCl_3$, 300 MHz) δ 7.61 (2H, dd), 7.52 (1H, d, J =7.69 Hz), 7.50-7.26 (10H, m), 7.04 (3H, m), 3.14-3.14 (4H, m), 2.57 (4H, br s), 2.33 (3H, s).

Example 2

N-(4-Chlorobenzyl)-3-[2-(4-methylpiperazin-1-yl)phenyl]-2-phenylacrylamide hydrochloride

[0097] A mixture of (4.0 g, 25.9 mmol) of phenylacetyl chloride, 3.15 mL (25.9 mmol) of 4-chlorobenzylamine and 5.1 mL of triethylamine in 120 mL of methylene chloride was prepared at 0°C and then heated to reflux under a nitrogen atmosphere for 18 hours. The solvent was evaporated and the residue was treated with 2 mL of 4-chlorobenzylamine and 3 mL of triethylamine and reheated to reflux overnight. After cooling, the mixture was suspended in 100 mL of methylene chloride, washed with 0.5 N hydrochloric acid, 0.5 N sodium hydroxide and saturated aqueous sodium chloride, followed by drying with magnesium sulfate ($MgSO_4$). The solvent was removed *in vacuo* to give a white solid which was recrystallized from ethyl acetate:hexane to provide N-(4-chlorobenzyl)-phenylacetamide as a white crystalline solid, 4.15 g (62%).

[0098] A mixture of 2-(4-methylpiperazin-1-yl)benzaldehyde (0.091 g, 0.45 mmol), N-(4-chlorobenzyl)-phenylacetamide (0.127 g, 0.49 mmol) and N,N-dimethylformamide (2 mL) was treated with anhydrous sodium methoxide (0.072 g, 1.34 mmol) under a nitrogen atmosphere as above to give the title product as an amorphous solid, (0.029 g).

Mass spectrum: 446 (100%, M^{+1}), 448 (76%, M^{+3}).

1H -NMR ($CDCl_3$, 300 MHz) δ 8.15 (1H, s), 7.45-6.9 (11H, m), 6.70 (1H, t), 6.60 (1H, d), 5.95 (1H, t), 4.50 (1H, d), 3.6 (4H, m), 3.25 (4H, m), 2.90 (3H, s).

Example 3

N-(4-Chlorobenzyl)-3-[2-(4-methylpiperazin-1-yl)phenyl]-acrylamide

[0099] A mixture of (0.106 g, 0.41 mmol) of N-(4-chlorobenzyl)-phenylacetamide and 5.0 mL of acetic anhydride was heated to 100°C for 18 hours, cooled to room temperature and neutralized with an excess of aqueous saturated sodium bicarbonate to a pH of approximately 7. The product was extracted into methylene chloride, which was washed with saturated aqueous sodium chloride, dried with magnesium sulfate and concentrated *in vacuo*. The resulting foam was flash chromatographed on silica gel using hexane and ethyl acetate to elute 0.039 g of the crude intermediate, N-acetyl-N-(4-chlorobenzyl)-phenylacetamide, as a colorless oil.

[0100] In a flame-dried 25 mL 3-neck round bottom flask equipped with a magnetic stir bar, 83 mg (2.07 mmol of a 60% oil dispersion) of sodium hydride was washed with hexane and covered with 1.0 mL of anhydrous N,N-dimethylformamide (DMF). To this was added 156 mg (0.517 mmol) of N-acetyl-N-(4-chlorobenzyl)phenylacetamide (prepared as above) and 84 mg (0.414 mmol) of 2-(4-methylpiperazin-1-yl)benzaldehyde with an additional 1 mL of DMF. The brown reaction mixture was stirred at 25°C for 48 hours, diluted with ethyl acetate, washed with 1N lithium chloride

(LiCl) followed by saturated aqueous sodium chloride. The organic layer was dried over calcium sulfate (CaSO₄) and concentrated to an oil which was crystallized from about 1 mL of boiling ethyl acetate to give the title product as colorless crystals, 20 mg, m.p. 193-194°C.

Mass spectrum: 370 (M⁺¹).

5 ¹H-NMR (CDCl₃, 300 MHz) δ 8.05 (1H, d), 7.49 (1H, dd), 7.39-7.24 (5H, m), 7.10-7.00 (2H, m), 6.39 (1H, t), 4.56 (2H, d), 3.00 (4H, t), 2.63 (4H, br s), 2.37 (3H, s).

Example 4

10 3-[2-(4-Methylpiperazin-1-yl)phenyl]-N-(4-trifluoromethylphenyl)-acrylamide

[0101] In a flame-dried 3-neck round bottom flask equipped with a magnetic stir bar, sodium hydride (50 mg, 1.25 mmol of a 60% oil dispersion) was washed with hexane and covered with 6.0 mL of anhydrous dimethylformamide (DMF). To this was added a solution of 3-(4-trifluoromethylphenyl)-thiazolidine-2,4-dione (240 mg, 0.92 mmol) and 2-(4-methylpiperazin-1-yl)benzaldehyde (170 mg, 0.84 mmol) in 2 mL of DMF. After stirring at room temperature overnight the mixture was heated to reflux for 4 hours and cooled. The solvent was removed *in vacuo* and the residue partitioned between saturated aqueous ammonium chloride and chloroform. The organic layer was washed with saturated NaCl, dried and filtered. The residue was absorbed onto silica gel (640 mg) and flash chromatographed on a 4 X 0.75 in column eluting with ethyl acetate: hexanes (3:1) followed by 100% ethyl acetate. The crude product oil was dissolved in hot EtOAc and allowed to cool to deposit 30 mg of yellow crystals which were filtered and dried, m.p. 207-209 °C.

Mass spectrum: 390 (M⁺¹)

15 ¹H-NMR (CDCl₃, 300 MHz) δ 8.19 (1H, d), 7.78 (2H, d), 7.62 (2H, d), 7.55 (1H, dd), 7.45 (1H, br s), 7.37 (1H, dt), 7.11-7.04 (2H, m), 6.53 (1H, d), 3.02 (4H, t), 2.65 (4H, br s), 2.38 (3H, s).

20 Elemental Analysis: Calculated for C₂₁H₂₂F₃N₃O: C 64.77, H 5.69, N 10.79. Found: C 64.51, H 5.70, N 10.77.

25

Example 5

N-(3,4-Dichlorophenyl)-3-[2-(4-methylpiperazin-1-yl)phenyl]-acrylamide

[0102] In a flame-dried 3-neck round bottom flask containing a magnetic stir bar, water condenser and dry nitrogen (N₂) inlet were placed 2-(4-methylpiperazin-1-yl)-aniline (0.200 g, 1.05 mmol) and 50% aqueous tetrafluoroboric acid (HBF₄)(0.33 ml, 2.63 mmol). To the stirred mixture, sodium nitrite (0.076 g, 1.10 mmol) in 2 mL of water was added and stirring was continued at 0°C for 30 minutes. A solution of N-(3,4-dichlorophenyl)-acrylamide (0.454 g, 2.1 mmol) in 4 mL of methanol, followed by palladium (II) acetate (5 mg) were then added and the reaction was refluxed for 30 minutes. After allowing the reaction to cool, the solvent was removed *in vacuo* and the residue was partitioned between ethyl acetate and saturated aqueous sodium carbonate. The organic layer was washed with saturated brine and dried with CaSO₄, filtered and concentrated *in vacuo* to a crude dark solid. Chromatography on silica gel, eluting with 75% ethyl acetate:hexanes, 100% ethyl acetate and finally 0.5% methanol: ethyl acetate provided a yellow solid, 0.221 g which was recrystallized from ethyl acetate to give the title product, 0.120 g.

40 m.p. 192-193 °C

Mass spectrum: 390 (M⁺¹)

45 ¹H-NMR (CDCl₃, 400 MHz) δ 8.14 (1H, d), 7.91 (1H, d), 7.46 (1H, dd), 7.44-7.32 (4H, m), 7.07-7.00 (2H, m), 6.46 (1H, d), 2.98 (4H, t), 2.62 (4H, br s), 2.35 (3H, s).

Elemental Analysis: Calculated for C₂₀H₂₁Cl₂N₃O: C 61.54, H 5.42, N 10.77. Found: C 61.14, H 5.36, N 10.63.

45

Preparation 1

N-(3,4-dichlorophenyl)-acrylamide

[0103] A mixture of 3,4-dichloroaniline (3.6 g, 22.3 mmol) and 4.2 mL (30.2 mmol) of triethylamine in 20 mL of anhydrous methylene chloride was cooled to 0 °C under a nitrogen atmosphere and treated with acryloyl chloride (2.1 g, 23.2 mmol). The ice bath was removed and the mixture was stirred at room temperature for 1 hour after which time it was diluted with 120 mL of methylene chloride and washed with water and saturated aqueous sodium chloride (NaCl). After drying with calcium sulfate (CaSO₄), the solvent was removed *in vacuo* to give a yellow solid, 4.84 g.

55 Mass spectrum: 216 (M⁺¹)

Preparation 22-(4-methylpiperazin-1-yl)-aniline

5 [0104] A mixture of 2-fluoronitrobenzene (6.0 mL, 56.9 mmol) and N-methylpiperazine (8.11 mL, 56.9 mmol) was stirred at 0 °C for 20 minutes, then at room temperature for 3 days. The crude mixture was partitioned between methylene chloride and saturated aqueous sodium bicarbonate and the organic layer was then washed with saturated sodium chloride (NaCl), dried and concentrated in vacuo to provide 2-(4-methylpiperazin-1-yl)-1-nitrobenzene as an orange oil, 12.4 g.


10 ¹H-NMR (CDCl₃, 300 MHz) δ 7.75 (1H, dd), 7.47 (1H, dt) 7.15 (1H, dd), 7.03 (1H, dt), 3.09 (1H, dd), 2.56 (1H, dd), 2.36 (3H, s).

[0105] The above oil (12.4 g, 56.2 mmol) in 110 mL of methanol was hydrogenated with 1.2 g of 10% palladium on carbon (Pd on C) in a Parr shaker apparatus at an initial hydrogen pressure of 50 psi for approximately 30 minutes. The solution was then filtered through a pad of diatomaceous earth (d.e.). The d.e. was rinsed with additional methanol 15 and the filtrate was concentrated in vacuo to give 10.0 g (93%) of 2-(4-methylpiperazin-1-yl)-aniline as an off-white solid.


¹H-NMR (CDCl₃, 300 MHz) δ 7.05 (1H, d), 6.95 (1H, dt) 6.76 (2H, dt), 3.97 (2H, br s), 2.96 (4H, t), 2.63 (4H, br s), 2.37 (3H, s).

20 **Claims**

1. A compound of the formula



35 wherein R¹ is a group of the formula G¹, G², G³, G⁴ or G⁵, depicted below,



50 G¹ G² G³

5

10

15

20

25

30


35

40

45

50

55

G⁴G⁵

wherein E is oxygen, sulfur, SO or SO₂;

R⁶ is selected from the group consisting of hydrogen, (C₁-C₆)alkyl, [(C₂-C₄)alkyl]aryl wherein the aryl moiety is phenyl, naphthyl, or heteroaryl-(CH₂)_q-, wherein the heteroaryl moiety is selected from the group consisting of pyridyl, pyrimidyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl and benzisothiazolyl and q is zero, one, two, three or four, and wherein said aryl and heteroaryl moieties may optionally be substituted with one or more substituents independently selected from the group consisting of chloro, fluoro, bromo, iodo, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, trifluoromethyl, cyano and -SO_g(C₁-C₆)alkyl, wherein g is zero, one or two;

R⁷ is selected from the group consisting of hydrogen, (C₁-C₆)alkyl, [(C₂-C₄)alkyl]aryl wherein the aryl moiety is phenyl, naphthyl, or heteroaryl-(CH₂)_q-, wherein the heteroaryl moiety is selected from the group consisting of pyridyl, pyrimidyl, benzoxazolyl, benzothiazolyl, benzisoxazolyl and benzisothiazolyl and q is zero, one, two, three or four, and wherein said aryl and heteroaryl moieties may optionally be substituted with one or more substituents independently selected from the group consisting of chloro, fluoro, bromo, iodo, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, trifluoromethyl, -C(=O)-(C₁-C₆)alkyl, cyano and -SO_j(C₁-C₆)alkyl, wherein j is zero, one or two; or R⁶ and R⁷ together form a 2 to 4 carbon chain;

R⁸ is hydrogen or (C₁-C₃) alkyl;

R⁹ is hydrogen or (C₁-C₆)alkyl;

or R⁶ and R⁹, together with the nitrogen atom to which they are attached, form a 5 to 7 membered ring; and p is one, two, or three;

R² is hydrogen, (C₁-C₄)alkyl, phenyl or naphthyl, wherein said phenyl or naphthyl may optionally be substituted with one or more substituents, preferably from zero to three substituents, independently selected from the group consisting of chloro, fluoro, bromo, iodo, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, trifluoromethyl, cyano and -SO_g(C₁-C₆)alkyl, wherein g is zero, one or two;

R³ is -(CH₂)_mB, wherein m is zero, one, two or three and B is hydrogen, phenyl, naphthyl or a 5 or 6 membered heteroaryl group containing from one to four hetero atoms in the ring, and wherein each of the foregoing aryl and heteroaryl groups may optionally be substituted with one or more substituents, preferably from zero to three substituents, independently selected from the group consisting of chloro, fluoro, bromo, iodo, (C₁-C₆)alkyl, (C₁-C₆)alkoxy, trifluoromethyl, cyano, hydroxy, -COOH and -SO_g(C₁-C₆)alkyl, wherein g is zero, one or two;

R⁴ is (C₁-C₆)alkyl or aryl or R³ and R⁴ may optionally be taken together with the nitrogen to which they are attached to form a five to seven membered heteroalkyl ring, wherein any two of the carbon atoms of said heteroalkyl ring may optionally be replaced with a heteroatom selected from the group consisting of nitrogen, oxygen or sulfur; wherein said heteroalkyl ring may optionally be substituted by aryl or heteroaryl;

R⁵ is hydrogen, (C₁-C₆)alkyl or aryl, wherein aryl is selected from the group consisting of phenyl, naphthyl, pyridyl or pyrimidyl, wherein any of said aryl may optionally be independently substituted on any available bonding site by any of the radicals of X;

X is hydrogen, chloro, fluoro, bromo, iodo, cyano, (C₁-C₆)alkyl, hydroxy, trifluoromethyl, (C₁-C₆)alkoxy, -SO_m(C₁-C₆)alkyl wherein m is zero one or two, -CO₂R¹⁰ or -CONR¹¹R¹²;

each of R¹⁰, R¹¹ and R¹² is selected, independently, from the radicals set forth in the definition of R²; or R¹¹ and R¹², together with the nitrogen to which they are attached, form a 5 to 7 membered ring that may contain from one to four heteroatoms selected from nitrogen, sulfur and oxygen;
 the broken lines represent optional double bonds;
 or a pharmaceutically acceptable salt thereof.

5 2. A compound according to claim 1, wherein R¹ is



15 G¹

and R⁶ is methyl.

20 3. A compound according to claim 1 wherein R³ is substituted phenyl or -(CH₂)-substituted phenyl.

4. A compound according to claim 2 wherein R³ is substituted phenyl or -(CH₂)-substituted phenyl.

25 5. A compound according to claim 2 wherein R² is hydrogen, R⁴ and R⁵ are hydrogen or methyl, and X is hydrogen, fluoro or chloro.

6. A compound according to claim 3 wherein R² is hydrogen, R⁴ and R⁵ are hydrogen or methyl, and X is hydrogen, fluoro or chloro.

30 7. A compound according to claim 4 wherein R² is hydrogen, R⁴ and R⁵ are hydrogen or methyl, and X is hydrogen, fluoro or chloro.

8. The compound of claim 1, said compound being selected from:

35 3-[2-(4-methylpiperazin-1-yl)phenyl]-2,N-diphenyl-acrylamide;
 3-[2-(4-methylpiperazin-1-yl)phenyl]-N-(4-trifluoro-methylphenyl)-acrylamide;
 N-(3,4-dichlorophenyl)-3-[2-(4-methylpiperazin-1-yl)phenyl]-acrylamide;
 N-(4-chlorobenzyl)-3-[2-(4-methylpiperazin-1-yl)-phenyl]-2-phenylacrylamide; and
 N-(4-chlorobenzyl)-3-[2-(4-methylpiperazin-1-yl)-phenyl]acrylamide.

40 9. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier.

45 10. Use of a compound according to claim 1 in the manufacture of a medicament for treating or preventing a disorder or condition selected from hypertension, depression, generalized anxiety disorder, phobias, posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation, eating disorders, obesity, chemical dependencies, cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders, Parkinson's disease, endocrine disorders, vasospasm, cerebellar ataxia, gastrointestinal tract disorders where changes in motility and secretion are involved, and chronic paroxysmal hemicrania and headache associated with vascular disorders.

50 11. Use of a compound according to claim 1 in the manufacture of a medicament for treating or preventing a disorder or condition that can be treated or prevented by enhancing serotonergic neurotransmission.

55 12. A pharmaceutical composition comprising:


a) a pharmaceutically acceptable carrier;
 b) a compound according to claim 1; and

c) a 5-HT re-uptake inhibitor or a pharmaceutically acceptable salt thereof.


5 13. Pharmaceutical products containing a compound according to claim 1; and a 5-HT re-uptake inhibitor, or a pharmaceutically acceptable salt thereof; as a combined preparation for simultaneous, separate or sequential use in treating or preventing a disorder or condition that can be treated or prevented by enhancing serotonergic neuro-transmission.

10 **Patentansprüche**

15 1. Verbindung der Formel



25 worin R¹ eine Gruppe der Formel G¹, G², G³, G⁴ oder G⁵, wie unten dargestellt, ist:



40 G¹

G²

G³

45


50

55

5

10

15

G⁴G⁵

worin E Sauerstoff, Schwefel, SO oder SO₂ ist;

20 R⁶ ausgewählt ist aus der Gruppe bestehend aus Wasserstoff, (C₁-C₆)-Alkyl-, [(C₂-C₄)-Alkyl]arylgruppen, worin der Arylanteil ein Phenyl-, Naphthyl- oder Heteroaryl-(CH₂)_q-Anteil ist, wobei der Heteroarylanteil ausgewählt ist aus der Gruppe bestehend aus Pyridyl-, Pyrimidyl-, Benzoxazolyl-, Benzothiazolyl-, Benzisoxazolyl- und Benzisothiazolylgruppen und q 0, 1, 2, 3 oder 4 ist, und wobei die Aryl- und Heteroarylanteile gegebenenfalls mit einem oder mehreren Substituenten substituiert sein können, die unabhängig ausgewählt sind aus der Gruppe bestehend aus Chlor, Fluor, Brom, Iod, (C₁-C₆)-Alkyl-, (C₁-C₆)-Alkoxy-, Trifluormethyl-, Cyano- und -SO₂-(C₁-C₆)-Alkylgruppen, wobei g 0, 1 oder 2 ist;

25 R⁷ ausgewählt ist aus der Gruppe bestehend aus Wasserstoff, (C₁-C₆)-Alkyl-, [(C₂-C₄)-Alkyl]arylgruppen, worin der Arylanteil ein Phenyl-, Naphthyl- oder Heteroaryl-(CH₂)_q-Anteil ist, wobei der Heteroarylanteil ausgewählt ist aus der Gruppe bestehend aus Pyridyl-, Pyrimidyl-, Benzoxazolyl-, Benzothiazolyl-, Benzisoxazolyl- und Benzisothiazolylgruppen und q 0, 1, 2, 3 oder 4 ist, und wobei die Aryl- und Heteroarylanteile gegebenenfalls mit einem oder mehreren Substituenten substituiert sein können, die unabhängig ausgewählt sind aus der Gruppe bestehend aus Chlor, Fluor, Brom, Iod, (C₁-C₆)-Alkyl-, (C₁-C₆)-Alkoxy-, Trifluormethyl-, -C(=O)-(C₁-C₆)-Alkyl-, Cyano- und -SO₂-(C₁-C₆)-Alkylresten, wobei j 0, 1 oder 2 ist; oder

30 R⁶ und R⁷ zusammen eine Kohlenstoffkette mit 2 bis 4 Kohlenstoffatomen bilden;

35 R⁸ Wasserstoff oder ein (C₁-C₃)-Alkylrest ist;

R⁹ Wasserstoff oder ein (C₁-C₆)-Alkylrest ist oder

40 R⁶ und R⁹ zusammen mit dem Stickstoffatom, an das sie gebunden sind, einen 5- bis 7-gliedrigen Ring bilden; p 1, 2 oder 3 ist;

45 R² Wasserstoff, ein (C₁-C₄)-Alkyl-, Phenyl- oder Naphthylrest ist, wobei der Phenyl- oder Naphthylrest gegebenenfalls mit einem oder mehreren Substituenten, bevorzugt 0 bis 3 Substituenten, substituiert sein kann, die unabhängig ausgewählt sind aus der Gruppe bestehend aus Chlor, Fluor, Brom, Iod, (C₁-C₆)-Alkyl-, (C₁-C₆)-Alkoxy-, Trifluormethyl-, Cyano- und -SO₂-(C₁-C₆)-Alkylresten, wobei g 0, 1 oder 2 ist;

R³ -(CH₂)_mB ist, worin m 0, 1, 2 oder 3 ist und B Wasserstoff, ein Phenyl- oder Naphthylrest oder eine 5- oder 6-gliedrige Heteroarylgruppe mit 1 bis 4 Heteroatomen im Ring ist, wobei jede der vorhergehenden Aryl- und Heteroarylgruppen gegebenenfalls mit einem oder mehreren Substituenten, bevorzugt 0 bis 3 Substituenten, substituiert sein kann die unabhängig ausgewählt sind aus der Gruppe bestehend aus Chlor, Fluor, Brom, Iod, (C₁-C₆)-Alkyl-, (C₁-C₆)-Alkoxy-, Trifluormethyl-, Cyano-, Hydroxyresten, -COOH und -SO₂-(C₁-C₆)-Alkylresten, worin g 0, 1 oder 2 ist;

50 R⁴ ein (C₁-C₆)-Alkylrest oder Arylrest ist oder R³ und R⁴ gegebenenfalls zusammen mit dem Stickstoffatom, an das sie gebunden sind, einen 5- bis 7-gliedrigen Heteroarylring bilden können, wobei irgendwelche zwei Kohlenstoffatome des Heteroalkylrings gegebenenfalls durch ein Heteroatom ersetzt sein können, das ausgewählt ist aus der Gruppe bestehend aus Stickstoff, Sauerstoff oder Schwefel; wobei der Heteroalkylring gegebenenfalls mit Aryl- oder Heteroarylresten substituiert sein kann;

55 R⁵ Wasserstoff, ein (C₁-C₆)-Alkyl- oder Arylrest ist, wobei der Arylrest ausgewählt ist aus der Gruppe bestehend aus Phenyl-, Naphthyl-, Pyridyl- oder Pyrimidylresten, wobei jeder der Arylreste gegebenenfalls unabhängig an irgendeiner verfügbaren Bindungsstelle mit irgendeinem der Reste X substituiert sein kann; X Wasserstoff, Chlor, Fluor, Brom, Iod, ein Cyano-, (C₁-C₆)-Alkyl-, Hydroxy-, Trifluormethyl-, (C₁-C₆)-Alkoxy-, -SO_m-(C₁-C₆)-Alkylrest ist, worin m 0, 1 oder 2 ist, -CO₂R¹⁰ oder -CONR¹¹R¹² ist;

jeder der Reste R¹⁰, R¹¹ und R¹² unabhängig ausgewählt ist aus den Resten, die für die Definition von R² angegeben sind oder R¹¹ und R¹² zusammen mit dem Stickstoffatom, an das sie gebunden sind, einen 5- bis 7-gliedrigen Ring bilden, der 1 bis 4 Heteroatome enthalten kann, die ausgewählt sind aus Stickstoff, Schwefel und Sauerstoff;

5 die durchbrochene Linie fakultative Doppelbindungen bedeutet oder ein pharmazeutisch annehmbares Salz davon.

2. Verbindung nach Anspruch 1, worin R¹

10

15

G¹

20 ist und R⁶ ein Methylrest ist.

3. Verbindung nach Anspruch 1, worin R³ ein substituierter Phenyl- oder-(CH₂)-substituierter Phenylrest ist.

4. Verbindung nach Anspruch 2, worin R³ ein substituierter Phenyl- oder-(CH₂)-substituierter Phenylrest ist.

25 5. Verbindung nach Anspruch 2, worin R² Wasserstoff ist, R⁴ und R⁵ Wasserstoff oder Methylreste sind und X Wasserstoff, Fluor oder Chlor ist.

30 6. Verbindung nach Anspruch 3, worin R² Wasserstoff ist, R⁴ und R⁵ Wasserstoff oder Methylreste sind und X Wasserstoff, Fluor oder Chlor ist.

7. Verbindung nach Anspruch 4, worin R² Wasserstoff ist, R⁴ und R⁵ Wasserstoff oder Methylreste sind und X Wasserstoff, Fluor oder Chlor ist.

35 8. Verbindung nach Anspruch 1, wobei die Verbindung ausgewählt ist aus:

3-[2-(4-Methylpiperazin-1-yl)phenyl]-2,N-diphenylacrylamid;
 3-[2-(4-Methylpiperazin-1-yl)phenyl]-N-(4-trifluormethylphenyl)acrylanid;
 N-(3,4-Dichlorphenyl)-3-[2-(4-methylpiperazin-1-yl)phenyl]acrylamid;
 40 N-(4-Chlorbenzyl)-3-[2-(4-methylpiperazin-1-yl)phenyl]-2-phenylacrylamid und
 N-(4-Chlorbenzyl)-3-[2-(4-methylpiperazin-1-yl)phenyl]-acrylamid.

45 9. Pharmazeutische Zusammensetzung enthaltend eine Verbindung nach Anspruch 1 und einen pharmazeutisch annehmbaren Träger.

10. Verwendung einer Verbindung nach Anspruch 1 zur Herstellung eines Arzneimittels zur Behandlung oder Verhütung einer Störung oder eines Zustandes ausgewählt aus Bluthochdruck, Depression, generalisierten Angstzuständen, Phobien, posttraumatischem Stresssyndrom, Meidungspersönlichkeitsstörung, vorzeitiger Ejakulation, Essstörungen, Fettsucht, chemischen Abhängigkeiten, Cluster-Kopfschmerz, Migräne, Schmerzen, Alzheimer-Krankheit, zwanghaften Störungen, panischen Störungen, Gedächtnisstörungen, Parkinson-Krankheit, endokrinen Störungen, Gefäßkrämpfe, Kleinhirnataxie, Störungen des Gastrointestinaltraktes, woran Veränderungen der Motilität und Sekretion beteiligt sind, und chronisch paroxysmaler Hämikranie und Kopfschmerz, der mit Gefäßleiden verbunden ist.

55 11. Verwendung einer Verbindung nach Anspruch 1 zur Herstellung eines Arzneimittels zur Behandlung oder Verhütung eines Leidens oder eines Zustandes, das/der behandelt oder verhindert werden kann, indem die serotonerge Neurotransmission verbessert wird.


12. Pharmazeutische Zusammensetzung umfassend:

5 a) einen pharmazeutisch annehmbaren Träger;
 b) eine Verbindung nach Anspruch 1 und
 c) einen 5-HT-Reuptake-Inhibitor oder ein pharmazeutisch annehmbares Salz davon.




10 13. Pharmazeutische Produkte enthaltend eine Verbindung nach Anspruch 1 und einen 5-HT-Reuptake-Inhibitor oder
 ein pharmazeutisch annehmbares Salz davon als kombiniertes Präparat für die gleichzeitige, getrennte oder auf-
 einander folgende Verwendung zur Behandlung oder Verhütung eines Leidens oder eines Zustandes, das/der
 behandelt oder verhindert werden kann, indem die serotonerge Neurotransmission verbessert wird.

Revendications

15 1. Composé de formule



30 dans laquelle R¹ représente un groupe de formule G¹, G², G³, G⁴ ou G⁵ représentée ci-dessous




50

55

5

10

15



20

dans laquelle E représente l'oxygène, le soufre, un groupe SO ou SO₂ ;

25 R⁶ est choisi dans le groupe consistant en l'hydrogène, des groupes alkyle en C₁ à C₆, (alkyle en C₂ à C₄)-aryle dans lequel le groupement aryle est un groupe phényle, naphtyle ou hétéroaryl-(CH₂)_q-, dans lequel le groupement hétéroaryl est choisi dans le groupe consistant en les groupements pyridyle, pyrimidyle, benzoxazolyle, benzothiazolyle, benzisoxazolyle et benzisothiazolyle et q est égal à zéro, un, deux, trois ou quatre, lesdits groupements aryle, hétéroaryl pouvant être facultativement substitués avec un ou plusieurs substituants choisis indépendamment dans le groupe consistant en des substituants chloro, fluoro, bromo, iodo, alkyle en C₁ à C₆, alkoxy en C₁ à C₆, trifluorométhyle, cyano et -SO_g-(alkyle en C₁ à C₆) dans lequel g est égal à zéro, un ou deux ;

30 R⁷ est choisi dans le groupe consistant en l'hydrogène, des groupes alkyle en C₁ à C₆, (alkyle en C₂ à C₄)-aryle dans lequel le groupement aryle est un groupe phényle, naphtyle ou hétéroaryl-(CH₂)_q-, dans lequel le groupement hétéroaryl est choisi dans le groupe consistant en les groupements pyridyle, pyrimidyle, benzoxazolyle, benzothiazolyle, benzisoxazolyle et benzisothiazolyle et q est égal à zéro, un, deux, trois ou quatre, lesdits groupements aryle, hétéroaryl pouvant être facultativement substitués avec un ou plusieurs substituants choisis indépendamment dans le groupe consistant en des substituants chloro, fluoro, bromo, iodo, alkyle en C₁ à C₆, alkoxy en C₁ à C₆, trifluorométhyle, -C(=O)-(alkyle en C₁ à C₆), cyano et -SO_j-(alkyle en C₁ à C₆) dans lequel j est égal à zéro, un ou deux ;

35 ou bien R⁶ et R⁷, conjointement, forment une chaîne de 2 à 4 atomes de carbone ;

40 R⁸ représente l'hydrogène ou un groupe alkyle en C₁ à C₃, R⁹ représente l'hydrogène ou un groupe alkyle en C₁ à C₆, ou bien R⁶ et R⁹, conjointement avec l'atome d'azote auquel ils sont fixés, forment un noyau pentagonal ;

45 et p est égal à un, deux ou trois ;

R² représente l'hydrogène, un groupe alkyle en C₁ à C₄, phényle ou naphtyle, ledit groupe phényle ou naphtyle pouvant être facultativement substitué avec un ou plusieurs substituants, de préférence avec zéro à trois substituants, choisis indépendamment dans le groupe consistant en des substituants chloro, fluoro, bromo, iodo, alkyle en C₁ à C₆, alkoxy en C₁ à C₆, trifluorométhyle, cyano et -SO_g-(alkyle en C₁ à C₆) dans lequel g est égal à zéro, un ou deux ;

50 R³ représente un groupe -(CH₂)_mB, dans lequel m est égal à zéro, un, deux ou trois et B représente l'hydrogène, un groupe phényle, un groupe naphtyle ou un groupe hétéroaryl, penta- ou hexagonal contenant 1 à 4 hétéro-atomes dans le noyau, chacun des groupes aryle et hétéroaryl précités pouvant être facultativement substitué avec un ou plusieurs substituants, de préférence avec zéro à trois substituants, choisis indépendamment dans le groupe consistant en des substituants chloro, fluoro, bromo, iodo, alkyle en C₁ à C₆, alkoxy en C₁ à C₆, trifluorométhyle, cyano, hydroxy, -COOH et -SO_g-(alkyle en C₁ à C₆) dans lequel g est égal à zéro, un ou deux ;

55 R⁴ représente un groupe alkyle en C₁ à C₆ ou aryle, ou bien R³ et R⁴ peuvent être facultativement pris conjointement avec l'atome d'azote auquel ils sont fixés pour former un noyau hétéroalkyle, penta- à heptagonal, deux quelconques des atomes de carbone dudit noyau hétéroalkyle pouvant être facultativement remplacés

par un hétéro-atome choisi dans le groupe consistant en l'azote, l'oxygène et le soufre ; ledit noyau hétéroalkyle pouvant être facultativement substitué avec un substituant aryle ou hétéroaryle ;
 5 R⁵ représente l'hydrogène, un groupe alkyle en C₁ à C₆ ou aryle, ledit groupe aryle étant choisi dans le groupe consistant en les groupes phényle, naphtyle, pyridyle et pyrimidyle, n'importe lequel desdits groupes aryle pouvant être facultativement substitué indépendamment sur n'importe quel site de liaison disponible avec n'importe lequel des radicaux de X ;
 X représente l'hydrogène, un groupe chloro, fluoro, bromo, iodo, cyano, alkyle en C₁ à C₆, hydroxy, trifluorométhyle, alkoxy en C₁ à C₆, -SO_m-(alkyle en C₁ à C₆) dans lequel m est égal à zéro, un ou deux, -CO₂R¹⁰ ou -CONR¹¹R¹² ;
 10 chacun des groupes R¹⁰, R¹¹ et R¹² est choisi, indépendamment, parmi les radicaux présentés dans la définition de R² ; ou bien R¹¹ et R¹², conjointement avec l'atome d'azote auquel ils sont fixés, forment un noyau penta- à heptagonal qui peut contenir 1 à 4 hétéro-atomes choisis entre l'azote, le soufre et l'oxygène ; les lignes discontinues représentent des doubles liaisons facultatives ;
 15 ou un de ses sels pharmaceutiquement acceptables.

15 2. Composé suivant la revendication 1, dans lequel R¹ représente un groupe



25 G¹

et R⁶ représente un groupe méthyle.

30 3. Composé suivant la revendication 1, dans lequel R³ représente un groupe phényle substitué ou phényl-(CH₂)-substitué.

40 4. Composé suivant la revendication 2, dans lequel R³ représente un groupe phényle substitué ou phényl-(CH₂)-substitué.

45 5. Composé suivant la revendication 2, dans lequel R² représente l'hydrogène, R⁴ et R⁵ représentent l'hydrogène ou des groupes méthyle, et X représente l'hydrogène, un groupe fluoro ou chloro.

6. Composé suivant la revendication 3, dans lequel R² représente l'hydrogène, R⁴ et R⁵ représentent l'hydrogène ou des groupes méthyle, et X représente l'hydrogène, un groupe fluoro ou chloro.

7. Composé suivant la revendication 4, dans lequel R² représente l'hydrogène, R⁴ et R⁵ représentent l'hydrogène ou des groupes méthyle, et X représente l'hydrogène, un groupe fluoro ou chloro.

8. Composé suivant la revendication 1, ledit composé étant choisi entre les suivants :

45 3-[2-(4-méthylpipérazine-1-yl)phényl]-2-N-diphényl-acrylamide ;
 3- [2- (4-méthylpipérazine-1-yl)phényl] -N- (4-trifluoro-méthylphényl) -acrylamide ;
 N-(3,4-dichlorophényl)-3 - [2-(4-méthylpipérazine-1-yl)-phényl]-acrylamide ;
 N-(4-chlorobenzyl)-3-[2-(4-méthylpipérazine-1-yl)-phényl]-2-phénylacrylamide ; et
 50 N-(4-chlorobenzyl)-3-[2-(4-méthylpipérazine-1-yl)-phényl]-acrylamide.

9. Composition pharmaceutique comprenant un composé suivant la revendication 1 et un support pharmaceutiquement acceptable.

55 10. Utilisation d'un composé suivant la revendication 1 dans la production d'un médicament destiné au traitement ou à la prévention d'un trouble ou d'une affection faisant partie du groupe comprenant l'hypertension, la dépression, le syndrome d'anxiété généralisée, des phobies, le syndrome de stress post-traumatique, le syndrome d'évitement affectif, l'éjaculation prématuée, des troubles de l'alimentation, l'obésité, des dépendances chimiques, les cépha-

lées vasculaires de Horton, la migraine, la douleur, la maladie d'Alzheimer, le syndrome obsessionnel compulsif, la panique, des troubles de la mémoire, la maladie de Parkinson, des troubles endocriniens, un angiospasme, l'ataxie cérébelleuse, des troubles du tractus gastro-intestinal impliquant des modifications de la motivité et de la sécrétion, et l'hémicrânie paroxystique chronique et les céphalées associées à des troubles vasculaires.

5

11. Utilisation d'un composé suivant la revendication 1 dans la production d'un médicament destiné au traitement ou à la prévention d'un trouble ou d'une affection qui peut être traité ou prévenu en augmentant la neurotransmission sérotoninergique.

10

12. Composition pharmaceutique comprenant :

- a) un support pharmaceutiquement acceptable ;
- b) un composé suivant la revendication 1 ; et
- c) un inhibiteur de réabsorption de 5-HT ou un de ses sels pharmaceutiquement acceptables.

15

13. Produits pharmaceutiques contenant un composé suivant la revendication 1 ; et un inhibiteur de réabsorption de 5-HT ou un de ses sels pharmaceutiquement acceptables, sous forme d'une préparation mixte ou à des fins d'utilisation simultanée, séparée ou séquentielle dans le traitement ou la prévention d'un trouble ou d'une affection qui peut être traité ou prévenu en augmentant la neurotransmission sérotoninergique.

20

25

30

35

40

45

50

55